表紙：ウェアラブルインジェクターの世界市場（第7版）：デバイスタイプ別（パッチポンプ／オンボディインジェクター／ウェアラブル輸液ポンプ）、使用性別、治療領域別、主要地域別：業界動向と予測（2023年～2035年）

市場調査レポート

商品コード

1337366

ウェアラブルインジェクターの世界市場（第7版）：デバイスタイプ別（パッチポンプ／オンボディインジェクター／ウェアラブル輸液ポンプ）、使用性別、治療領域別、主要地域別：業界動向と予測（2023年～2035年）

Wearable Injectors Market (7th Edition): Distribution by Type of Device (Patch Pump / On Body Injector and Wearable Infusion Pump), Usability, Therapeutic Area and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

出版日: 2023年08月21日 | 発行: Roots Analysis

| ページ情報: 英文 644 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,799 752,291円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (One-Location Site License)

USD 6,999 1,097,163円

レポートPDFを同一所在地における特定事業ユニットに属する全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Department License)

USD 10,599 1,661,499円

レポートPDFを部署単位で12名様までご利用いただけるライセンスです。同一部署内であれば、地理的に同じ地点に存在する必要はありません。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 17,999 2,821,523円

レポートPDFを同社の国内外拠点における全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

1mLを超える量の薬剤を安全に自己投与できるウェアラブルインジェクターに対する需要の高まりは、その大きな利点によってもたらされています。これらのデバイスは、頻繁な病院受診や針刺し損傷のリスクを排除することにより、患者に高いレベルの利便性を提供します。インスリン投与によく使われるウェアラブル輸液ポンプは、1日に何度も針を刺すことを防ぐことで、糖尿病患者により良質なコントロールを提供します。さらに、パッチポンプとしても知られるオンボディインジェクターは、投与プロセスを簡素化し、リマインダーや追跡機能を提供することで、大量の投薬や頻繁な投与を必要とする患者に効果的なソリューションを提供します。これらのウェアラブルインジェクターは汎用性が高いため、糖尿病、自己免疫疾患、心血管疾患などの幅広い病状に適しています。加えて、ウェアラブルインジェクターは、がんなどの他の適応症のための薬剤を送達することができます。ウェアラブルインジェクターが提供する大きな利点は、世界の製薬業界やヘルスケア分野での需要の高まりと相まって、予測期間中の市場成長を促進するとみられています。

ウェアラブル輸液ポンプは、コンパクトで軽量な装置であり、カニューレを装着したベルトを患者に装着して使用します。これらのドラッグデリバリー機器は、体外注入器としても知られています。これらは、長期にわたる持続的または断続的な注入を必要とする患者に最適で、治療中に自由に動くことができます。ほとんどのインスリンポンプはベルトに装着するタイプで、ポンプと輸液セットをつなぐチューブが皮下脂肪組織に留置されています。

Neulasta Onproウェアラブルインジェクターは、2015年に承認を取得した最初の薬物デバイスの組み合わせであり、それ以来、様々な薬物デバイスの組み合わせが承認を取得しています。2016年、アムジェンは抗体医薬を送達する初の体内注射器を発売しました。同社のPushtronexシステムはWest Pharmaceuticals社のSmartDoseを使用し、ヘテロ接合性家族性高コレステロール血症（HeFH）または臨床的アテローム性動脈硬化性心血管疾患（ASCVD）を有する成人の治療薬として承認されているレパサ（エボロクマブ）を送達します。レパサのウェアラブルインジェクターは、患者に毎月1回投与するオプションを提供します。さらに、EVER Pharma社が提供するD-mine輸液ポンプが2019年に販売されました。この薬剤デバイスの組み合わせは、マイクロ回転ポンプ技術による自動投与機能を有します。2022年には、AbbVie社がクローン病治療に使用される体内注射器Skyriziを発売しました。このような非インスリン製剤の薬物併用承認が、ウェアラブルインジェクター市場の成長を後押ししています。複数の製薬会社がウェアラブルインジェクター開発者と協力して、臨床試験でデバイスをテストしているため、予測期間中にこのような薬物デバイスの承認が増えると予想されます。さらに、ウェアラブルインジェクター開発企業が受けた資金により、既存の設計に技術的進歩を取り入れ、臨床試験でデバイスをテストすることが可能になっています。2022年2月、Enable InjectionsはシリーズCベンチャー資金調達ラウンドで2億1,500万米ドルを調達しました。このような市場開拓は、予測期間中もウェアラブルインジェクター市場の成長を促進すると思われます。

世界のウェアラブルインジェクターの市場規模は、2023年に43億米ドルに達すると予測されています。様々な慢性疾患の治療に対する効果的な治療薬への需要が高まっていることから、予測期間中に9.01％のCAGRで拡大すると見込まれています。現在、市場の50％近くを北米の企業が占めています。米国ではウェアラブルインジェクターへの関心が高まっており、このようなデバイスが採用されていることから、北米のウェアラブルインジェクター市場は予測期間の2023-年～2035年に10.56％のCAGRで成長すると予測されています。さらに、償還の利用可能性は、そのようなデバイスの高価格帯のために、ウェアラブルインジェクターの市場成長を独占する重要な要因になるとみられています。

当レポートでは、世界のウェアラブルインジェクター市場について調査し、市場の概要とともに、デバイスタイプ別、使用性別、治療領域別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

List of Tables

Table 6.1 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Status of Development, Type of Device and Usability
Table 6.2 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Type of Dose, Type of Drug Container and Mode of Drug Filling
Table 6.3 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Container Volume (mL), Route of Administration and Mode of Injection
Table 6.4 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Mechanism of Action / Driving Force and Type of Technology
Table 6.5 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Availability of Connectivity Feature and Type of Compatible Drug
Table 6.6 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Compatibility with High Viscosity Drugs and Therapeutic Area
Table 6.7 Large Volume Wearable Injectors for Non-Insulin Drugs: List of Device Developers
Table 7.1 Large Volume Drug Device Combinations for Non-Insulin Drugs: Information on Status of Development, Type of Device and Usability
Table 7.2 Large Volume Drug Device Combinations for Non-Insulin Drugs: Information on Type of Dose, Mode of Drug Filling, Type of Drug Container and Container Volume (mL)
Table 7.3 Large Volume Drug Device Combinations for Non-Insulin Drugs: Information on Route of Administration, Mode of Injection and Type of Compatible Drug
Table 7.4 Large Volume Drug Device Combinations for Non-Insulin Drugs: Information on Drug Delivery Technology, Mechanism of Action / Driving Force and Therapeutic Area
Table 7.5 Large Volume Wearable Injectors for Drug Device Combinations for Non-Insulin Drugs: List of Device Developers
Table 8.1 Large Volume Wearable Injectors for Insulin Drugs: Information on Status of Development, Type of Device and Usability
Table 8.2 Large Volume Wearable Injectors for Insulin Drugs: Information on Type of Dose, Mode of Drug Filling and Container Volume (mL)
Table 8.3 Large Volume Wearable Injectors for Insulin Drugs: Information on Type of Diabetes, Type of Combination Insulin and Period of Use (days)
Table 8.4 Large Volume Wearable Injectors for Insulin Drugs: Information on Type of Device Control Feature and Availability of Interoperable Device
Table 8.5 Large Volume Wearable Injectors for Insulin Drugs: Information on Availability of CGM /BGM system, Availability of Automatic Insulin Delivery / Artificial Pancreases and Type of Automated Insulin Delivery Feature
Table 8.6 Large Volume Wearable Injectors for Insulin Drugs: Information on Availability of Connectivity Feature and Waterproof Capabilities
Table 8.7 Large Volume Wearable Injectors for Insulin Drugs: List of Device Developers
Table 10.1 Large Volume Wearable Injectors: List of Companies Profiled
Table 10.2 CCBio: Company Overview
Table 10.3 CCBio: Device Portfolio
Table 10.4 CCBio: Recent Developments and Future Outlook
Table 10.5 E3D Elcam Drug Delivery Device: Company Overview
Table 10.6 E3D Elcam Drug Delivery Device: Device Portfolio
Table 10.7 E3D Elcam Drug Delivery Devices: Recent Developments and Future Outlook
Table 10.8 Enable Injections: Company Overview
Table 10.9 Enable Injections: Device Portfolio
Table 10.10 Enable Injections: Recent Developments and Future Outlook
Table 10.11 Gerresheimer: Company Overview
Table 10.12 Gerresheimer: Device Portfolio
Table 10.13 Gerresheimer: Recent Developments and Future Outlook
Table 10.14 Sonceboz: Company Overview
Table 10.15 Sonceboz: Device Portfolio
Table 10.16 Sonceboz: Recent Developments and Future Outlook
Table 10.17 Weibel CDS: Company Overview
Table 10.18 Weibel CDS: Device Portfolio
Table 10.19 Weibel CDS: Developments and Future Outlook
Table 10.20 West Pharmaceuticals: Company Overview
Table 10.21 West Pharmaceuticals: Device Portfolio
Table 10.22 West Pharmaceuticals: Developments and Future Outlook
Table 10.23 CeQur: Company Overview
Table 10.24 CeQur: Device Portfolio
Table 10.25 CeQur: Developments and Future Outlook
Table 10.26 Eli Lilly: Company Overview
Table 10.27 Eli Lilly: Device Portfolio
Table 10.28 Eli Lilly: Developments and Future Outlook
Table 10.29 Insulet: Company Overview
Table 10.30 Insulet: Device Portfolio
Table 10.31 Insulet: Developments and Future Outlook
Table 10.32 Medtronic: Company Overview
Table 10.33 Medtronic: Device Portfolio
Table 10.34 Medtronic: Developments and Future Outlook
Table 10.35 Medtrum Technology: Company Overview
Table 10.36 Medtrum Technology: Device Portfolio
Table 10.37 Medtrum Technology: Developments and Future Outlook
Table 10.38 Roche: Company Overview
Table 10.39 Roche: Device Portfolio
Table 10.40 Roche: Developments and Future Outlook
Table 10.41 SOOIL Development: Company Overview
Table 10.42 SOOIL Development: Device Portfolio
Table 10.43 SOOIL Development: Developments and Future Outlook
Table 11.1 Large Volume Drug Device Combination: 3 mL Micropump (Furosemide)
Table 11.2 Large Volume Drug Device Combination: 3M hMTS (Adalimumab)
Table 11.3 Large Volume Drug Device Combination: D-mine Pump (Apomorphine)
Table 11.4 Large Volume Drug Device Combination: On-body Infusor (Furosemide)
Table 11.5 Large Volume Drug Device Combination: Herceptin SC Injector (Herceptin)
Table 11.6 Large Volume Drug Device Combination: ND0612H Belt Pump (Levodopa / Carbidopa)
Table 11.7 Large Volume Drug Device Combination: ND0612L belt pump (Levodopa / Carbidopa)
Table 11.8 Large Volume Drug Device Combination: ND0612L next generation patch pump (Levodopa / Carbidopa)
Table 11.9 Large Volume Drug Device Combination: ND0701 (Apomorphine)
Table 11.10 Large Volume Drug Device Combination: ND0901 (Levodopa / Carbidopa)
Table 11.11 Large Volume Drug Device Combination: Neulasta Onpro On-Body Injector (Neulasta)
Table 11.12 Large Volume Drug Device Combination: Pushtronex System (Repatha)
Table 11.13 Large Volume Drug Device Combination: SMT-201 (Ketorolac)
Table 11.14 Large Volume Drug Device Combination: SMT-301 (Bupivacaine)
Table 11.15 Large Volume Drug Device Combination: The LUTREPULSE System (Lutrepulse)
Table 11.16 Large Volume Drug Device Combination: Trevyent (Treprostinil)
Table 11.17 Large Volume Drug Device Combination: Ultomris (Ravulizumab)
Table 12.1 Large Volume Wearable Injectors: List of Partnerships and Collaborations, 2015-2023
Table 13.1 Large Volume Wearable Injectors: List of Key Acquisitions, 2000-2023
Table 13.2 Non-Insulin Drug Delivery Devices: Likelihood of Players for Acquisition
Table 13.3 Insulin Delivery Devices: Likelihood of Players for Acquisition
Table 14.1 Patent Analysis: Prominent CPC Symbols
Table 14.2 Patent Analysis: List of Top CPC Symbols
Table 14.3 Patent Analysis: Most Popular CPC Symbols
Table 14.4 Patent Analysis: Summary of Benchmarking Analysis
Table 14.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 14.6 Patent Analysis: List of Leading Patents (by Highest Relative Valuation)
Table 15.1 Marketed Drugs: Most Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 15.2 Marketed Drugs: Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 15.3 Marketed Molecules: Less Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 15.4 Marketed Molecules: Least Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 15.5 Clinical Stage Drugs : Most Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 15.6 Clinical Stage Drugs: Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 15.7 Clinical Stage Drugs: Less Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 15.8 Clinical Stage Drugs: Least Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 17.1 List of Funding Instances, 2014-2023: Information on Company, Year of Funding, Type, Amount Invested and Investors
Table 18.1 List of Contract Manufacturing Organizations
Table 18.2 List of Medical Device Product Design and Development Companies
Table 19.1 General Guidelines for Market Authorization and Reimbursement for Medical Devices
Table 19.2 Device Classification: US
Table 19.3 Device Classification: Canada
Table 19.4 Data Requirements and Characteristics of Province-wide HTA Processes in Canada
Table 19.5 Device Classification: Mexico
Table 19.6 Device Classification: Europe
Table 19.7 List of CE Directives in Europe
Table 19.8 Conformity Assessment Modules in Europe
Table 19.9 Device Classification: Australia
Table 19.10 Medical Devices Reimbursement and Pricing Approval Process: Australia
Table 19.11 Device Classification: Brazil
Table 19.12 Device Classification: China
Table 19.13 Device Classification: India
Table 19.14 Device Classification: Japan
Table 19.15 Medical Devices Reimbursement Categories
Table 19.16 Device Classification: Medsafe
Table 19.17 Device Classification: Singapore
Table 19.18 Device Classification: South Korea
Table 19.19 Device Classification: South Africa
Table 19.20 Device Classification: Thailand
Table 19.21 Medical Devices Regulatory Landscape Summary
Table 19.22 Medical Devices Reimbursement Landscape Summary
Table 25.1 Company Snapshot: Qlibrium
Table 25.1 Company Snapshot: Medipacs
Table 25.2 Company Snapshot: Enable Injections
Table 25.3 Company Snapshot: Subcuject
Table 25.4 Company Snapshot: scPharmaceuticals
Table 25.5 Company Snapshot: Elcam Medical
Table 25.6 Company Snapshot: West Pharmaceutical Services
Table 25.7 Company Snapshot: Ypsomed
Table 25.8 Company Snapshot: Debiotech
Table 25.9 Company Snapshot: Sorrel Medical
Table 26.1 Large Volume Wearable Injectors: Overall Market Landscape
Table 26.2 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Status of Development
Table 26.3 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Device
Table 26.4 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Usability
Table 26.5 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Dose
Table 26.6 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Drug Filling
Table 26.7 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Drug Container
Table 26.8 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Container Volume (mL)
Table 26.9 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Route of Administration
Table 26.10 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Injection
Table 26.11 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Drug Compatibility
Table 26.12 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Mechanism of Action
Table 26.13 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Technology
Table 26.14 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability for Connectivity Feature
Table 26.15 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability for High Viscosity Drugs
Table 26.16 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Therapeutic Area
Table 26.17 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Year of Establishment
Table 26.18 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Company Size
Table 26.19 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Location of Headquarters
Table 26.20 Leading Players: Distribution by Number of Devices
Table 26.21 Large Volume Drug Device Combinations: Distribution by Status of Development
Table 26.22 Large Volume Drug Device Combinations: Distribution by Type of Device
Table 26.23 Large Volume Drug Device Combinations: Distribution by Usability
Table 26.24 Large Volume Drug Device Combinations: Distribution by Type of Dose
Table 26.25 Large Volume Drug Device Combinations: Distribution by Mode of Drug Filling
Table 26.26 Large Volume Drug Device Combinations: Distribution by Type of Drug Container
Table 26.27 Large Volume Drug Device Combinations: Distribution by Container Volume (mL)
Table 26.28 Large Volume Drug Device Combinations: Distribution by Route of Administration
Table 26.29 Large Volume Drug Device Combinations: Distribution by Mode of Injection
Table 26.30 Large Volume Drug Device Combinations: Distribution by Drug Compatibility
Table 26.31 Large Volume Drug Device Combinations: Distribution by Drug Delivery Technology
Table 26.32 Large Volume Drug Device Combinations: Distribution by Mechanism of Action / Driving Force
Table 26.33 Large Volume Drug Device Combinations: Distribution by Therapeutic Area
Table 26.34 Large Volume Wearable Injectors for Drug Device Combinations: Distribution by Year of Establishment
Table 26.35 Large Volume Wearable Injectors for Drug Device Combinations: Distribution by Company Size
Table 26.36 Large Volume Wearable Injectors for Drug Device Combinations: Distribution by Location of Headquarters
Table 26.37 Leading Players: Distribution by Number of Devices
Table 26.38 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Status of Development
Table 26.39 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Device
Table 26.40 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Usability
Table 26.41 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Dose
Table 26.42 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Mode of Drug Filling
Table 26.43 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Container Volume (mL)
Table 26.44 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Diabetes
Table 26.45 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Period of use (Days)
Table 26.46 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Interoperable Devices
Table 26.47 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Continuous Glucose Monitoring (CGM) / Blood Glucose Monitoring (BGM) System
Table 26.48 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Automatic Insulin Delivery (AID) / Artificial Pancreas
Table 26.49 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Automated Insulin Delivery
Table 26.50 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Connectivity Feature
Table 26.51 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Device Control Features
Table 26.52 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Waterproof Capabilities
Table 26.53 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Combination Insulin
Table 26.54 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Year of Establishment
Table 26.55 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Company by Size
Table 26.56 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Location of Headquarters
Table 26.57 Leading Players: Distribution by Number of Devices
Table 26.58 Gerresheimer: Annual Revenues, FY 2017- Q1 FY 2023 (EUR Million)
Table 26.59 West Pharmaceuticals: Annual Revenues, FY 2017- Q1 FY 2023 (USD Billion)
Table 26.60 Eli Lilly: Annual Revenues, FY 2017- Q1 FY 2023 (USD Billion)
Table 26.61 Insulet: Annual Revenues, FY 2017- Q1 FY 2023 (USD Million)
Table 26.62 Medtronic: Annual Revenues, FY 2017- FY 2023 (USD Billion)
Table 26.63 Roche: Annual Revenues, FY 2016- H1 FY 2021 (USD Billion)
Table 26.64 Partnerships and Collaborations: Distribution by Year of Partnership
Table 26.65 Partnerships and Collaborations: Distribution by Type of Partnership
Table 26.66 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 26.67 Partnerships and Collaborations: Distribution by Type of Partner
Table 26.68 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 26.69 Partnerships and Collaborations: Distribution by Type of Device
Table 26.70 Most Active Players: Distribution by Number of Partnerships
Table 26.71 Partnerships and Collaborations: Regional Distribution by Number of Partnership
Table 26.72 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 26.73 Patent Analysis: Distribution by Type of Patent
Table 26.74 Patent Analysis: Cumulative Distribution by Publication Year
Table 26.75 Patent Analysis: Distribution by Issuing Authority / Patent Offices Involved
Table 26.76 Patent Analysis: Cumulative Distribution by Type of Organization
Table 26.77 Leading Industry Players: Distribution by Number of Patents
Table 26.78 Leading Non-Industry Players: Distribution by Number of Patents
Table 26.79 Patent Analysis: Leading Individual Assignees
Table 26.80 Patent Analysis: Distribution of Patents by Age
Table 26.81 Large Volume Wearable Injectors: Patent Valuation
Table 26.82 Clinical Trial Analysis: Distribution by Trial Status
Table 26.83 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year
Table 26.84 Clinical Trial Analysis: Distribution of Enrolled Patients by Trial Registration Year
Table 26.85 Clinical Trial Analysis: Distribution by Trial Phase
Table 26.86 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 26.87 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and Trial Recruitment Status
Table 26.88 Clinical Trial Analysis: Distribution by Study Design
Table 26.89 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 26.90 Clinical Trial Analysis: Distribution by Number of Registered Trials
Table 26.91 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 26.92 Clinical Trial Analysis: Popular Large Volume Wearable Injectors: Distribution by Number of Registered Trials
Table 26.93 Clinical Trial Analysis Most Popular Large Volume Wearable Injectors: Phase-wise Distribution by Number of Trials
Table 26.94 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Table 26.95 Clinical Trial Analysis: Distribution of Trials by Recruitment Status and Geography
Table 26.96 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Recruitment Status and Geography
Table 26.97 Funding and Investments: Distribution by Distribution by Cumulative Number of Funding
Table 26.98 Funding and Investments: Distribution by Year and Amount Invested (USD Million)
Table 26.99 Funding and Investments: Distribution by Type of Funding
Table 26.100 Funding and Investments: Distribution by Type of Device and Number of Funding Instances
Table 26.101 Funding and Investments: Distribution by Target Disease Indication
Table 26.102 Leading Players: Distribution by Number of Funding Instances
Table 26.103 Leading Players: Distribution by Amount Invested (USD Million)
Table 26.104 Key Investors: Distribution by Number of Instances
Table 26.105 Funding and Investment: Distribution by Geography
Table 26.106 Healthcare Insurance Coverage in the US: Distribution by Type of Coverage
Table 26.107 Healthcare Insurance Coverage in the Canada: Distribution by Type of Coverage
Table 26.108 Healthcare Insurance Coverage in the UK: Distribution by Type of Coverage
Table 26.109 Healthcare Insurance Coverage in the France: Distribution by Type of Coverage
Table 26.110 Healthcare Insurance Coverage in the Germany: Distribution by Type of Coverage
Table 26.111 Healthcare Insurance Coverage in the Italy: Distribution by Type of Coverage
Table 26.112 Healthcare Insurance Coverage in the Spain: Distribution by Type of Coverage
Table 26.113 Healthcare Insurance Coverage in the Australia: Distribution by Type of Coverage
Table 26.114 Healthcare Insurance Coverage in the China: Distribution by Type of Coverage
Table 26.115 Healthcare Insurance Coverage in the Israel: Distribution by Type of Coverage
Table 26.116 Healthcare Insurance Coverage in the Japan: Distribution by Type of Coverage
Table 26.117 Healthcare Insurance Coverage in the New Zealand: Distribution by Type of Coverage
Table 26.118 Healthcare Insurance Coverage in the South Korea: Distribution by Type of Coverage
Table 26.119 Healthcare Insurance Coverage in the Taiwan: Distribution by Type of Coverage
Table 26.120 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) (USD Million)
Table 26.121 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.122 Large Volume Wearable Injectors Market for Non-Insulin Drugs, Distribution by Type of Device (USD Million)
Table 26.123 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) (USD Million)
Table 26.124 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.126 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) (USD Million)
Table 26.126 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.127 Large Volume Wearable Injectors Market for Non-Insulin Drugs, Distribution by Usability (USD Million)
Table 26.128 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022), (USD Million)
Table 26.129 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.130 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022), (USD Million)
Table 26.131 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.132 Large Volume Wearable Injectors Market for Non-Insulin Drugs, Distribution by Therapeutic Areas (USD Million)
Table 26.133 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Oncological Disorders, Historical Trends (2017-2022), (USD Million)
Table 26.134 Large Volume Wearable Injectors Market for Non- Insulin Drugs targeting Oncological Disorders, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.135 Large Volume Wearable Injectors Market for Non Insulin Drugs targeting Cardiovascular Disorders, Historical Trends (2017-2022), (USD Million)
Table 26.136 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Cardiovascular Disorders, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.137 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Autoimmune Disorders, Historical Trends (2017-2022), (USD Million)
Table 26.138 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Autoimmune Disorders, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.139 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Neurological Disorders, Historical Trends (2017-2022), (USD Million)
Table 26.140 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Neurological Disorders, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.141 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Other Disorders, Historical Trends (2017-2022), (USD Million)
Table 26.142 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Other Disorders, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.143Large Volume Wearable Injectors Market for Non-Insulin Drugs, Distribution by Geography (USD Million)
Table 26.144 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022), (USD Million)
Table 26.115 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.111 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022), (USD Million)
Table 26.116 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.117 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022), (USD Million)
Table 26.118 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.119 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) (USD Million)
Table 26.120 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.121 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) (USD Million)
Table 26.122 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.123 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Oncological Disorders in North America, Historical Trends (2017-2022) (USD Million)
Table 26.124 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Oncological Disorders in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.125 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Cardiovascular Disorders in North America, Historical Trends (2017-2022) (USD Million)
Table 26.126 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Cardiovascular Disorders in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.127 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Autoimmune Disorders in North America, Historical Trends (2017-2022) (USD Million)
Table 26.128 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Autoimmune Disorders in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.129 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Neurological Disorders in North America, Historical Trends (2017-2022) (USD Million)
Table 26.130 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Neurological Disorders in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.131 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Other Disorders in North America, Historical Trends (2017-2022) (USD Million)
Table 26.132 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Other Disorders in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.133 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) (USD Million)
Table 26.134 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.135 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) (USD Million)
Table 26.136 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.137 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) (USD Million)
Table 26.138 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.139 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) (USD Million)
Table 26.140 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.141 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) (USD Million)
Table 26.142 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.143 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Oncological Disorders in Europe, Historical Trends (2017-2022) (USD Million)
Table 26.144 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Oncological Disorders in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.145 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Cardiovascular Disorders in Europe, Historical Trends (2017-2022) (USD Million)
Table 26.146 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Cardiovascular Disorders in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.147 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Autoimmune Disorders in Europe, Historical Trends (2017-2022) (USD Million)
Table 26.148 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Autoimmune Disorders in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.149 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Neurological Disorders in Europe, Historical Trends (2017-2022) (USD Million)
Table 26.150 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Neurological Disorders in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)" "
Table 26.151 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Other Disorders in Europe, Historical Trends (2017-2022) (USD Million)
Table 26.152 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Other Disorders in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.153 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) (USD Million)
Table 26.154 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.155 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) (USD Million)
Table 26.156 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.157 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) (USD Million)
Table 26.158 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.159 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) (USD Million)
Table 26.160 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.161 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) (USD Million)
Table 26.162 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.163 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Oncological Disorders in Asia, Historical Trends (2017-2022) (USD Million)
Table 26.164 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Oncological Disorders in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.165 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Cardiovascular Disorders in Asia, Historical Trends (2017-2022) (USD Million)
Table 26.166 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Cardiovascular Disorders in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.167 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Autoimmune Disorders in Asia, Historical Trends (2017-2022) (USD Million)
Table 26.168 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Autoimmune Disorders in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.169 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Neurological Disorders in Asia, Historical Trends (2017-2022) (USD Million)
Table 26.170 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Neurological Disorders in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.171 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Other Disorders in Asia, Historical Trends (2017-2022), (USD Million)
Table 26.172 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Other Disorders in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.173 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) (USD Million)
Table 26.174 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.175 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends Trends (2017-2022) (USD Million)
Table 26.176 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.177 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) (USD Million)
Table 26.178 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.179 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) (USD Million)
Table 26.180 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.181 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) (USD Million)
Table 26.182 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.183 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Oncological Disorders in Latin America, Historical Trends (2017-2022) (USD Million)
Table 26.184 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Oncological Disorders in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.185 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Cardiovascular Disorders in Latin America, Historical Trends (2017-2022) (USD Million)
Table 26.186 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Cardiovascular Disorders in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.187 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Autoimmune Disorders in Latin America, Historical Trends (2017-2022) (USD Million)
Table 26.188 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Autoimmune Disorders in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.189 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Neurological Disorders in Latin America, Historical Trends (2017-2022) (USD Million)
Table 26.190 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Neurological Disorders in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.191 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Other Disorders in Latin America, Historical Trends (2017-2022) (USD Million)
Table 26.192 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Other Disorders in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.193 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) (USD Million)
Table 26.194 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.195 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.196 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.197 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) (USD Million)
Table 26.198 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.199 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) (USD Million)
Table 26.200 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.201 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) (USD Million)
Table 26.202 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.203 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Oncological Disorders in Middle East and North Africa, Historical Trends (2017-2022) (USD Million)
Table 26.204 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Oncological Disorders in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.205 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Cardiovascular Disorders in Middle East and North Africa, Historical Trends (2017-2022) (USD Million)
Table 26.206 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Cardiovascular Disorders in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.207 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Autoimmune Disorders in Middle East and North Africa, Historical Trends (2017-2022) (USD Million)
Table 26.208 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Autoimmune Disorders in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.209 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Neurological Disorders in Middle East and North Africa, Historical Trends (2017-2022) (USD Million)
Table 26.210 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Neurological Disorders in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.211 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Other Disorders in Middle East and North Africa, Historical Trends (2017-2022) (USD Million)
Table 26.212 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Other Disorders in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.213 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) (Million Units)
Table 26.214 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.215 Large Volume Wearable Injectors Market for Non-Insulin Drugs, Distribution by Type of Device (Million Units)
Table 26.216 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) (Million Units)
Table 26.217 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.218 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) (Million Units)
Table 26.219 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.220 Large Volume Wearable Injectors Market for Non-Insulin Drugs, Distribution by Usability(Million Units)
Table 26.221 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) (Million Units)
Table 26.222 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.223 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) (Million Units)
Table 26.224 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.225 Large Volume Wearable Injectors Market for Non-Insulin Drugs, Distribution by Therapeutic Areas (Million Units)
Table 26.226 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Oncological Disorders, Historical Trends (2017-2022) (Million Units)
Table 26.227 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Oncological Disorders, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.228 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Cardiovascular Disorders, Historical Trends (2017-2022) (Million Units)
Table 26.229 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Cardiovascular Disorders, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.230 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Autoimmune Disorders, Historical Trends (2017-2022) (Million Units)
Table 26.231 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Autoimmune Disorders, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.232 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Neurological Disorders, Historical Trends (2017-2022) (Million Units)
Table 26.233 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Neurological Disorders, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.234 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Other Disorders, Historical Trends (2017-2022) (Million Units)
Table 26.235 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Other Disorders, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.236 Large Volume Wearable Injectors Market for Non-Insulin Drugs, Distribution by Geography (Million Units)
Table 26.237 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) (Million Units)
Table 25.238 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.239 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) (Million Units)
Table 26.240 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.241 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) (Million Units)
Table 26.242 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.243 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) (Million Units)
Table 26.244 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.245 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) (Million Units)
Table 26.246 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.247 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Oncological Disorders in North America, Historical Trends (2017-2022) (Million Units)
Table 26.248 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Oncological Disorders in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.249 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Cardiovascular Disorders in North America, Historical Trends (2017-2022) (Million Units)
Table 26.250 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Cardiovascular Disorders in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.251 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Autoimmune Disorders in North America, Historical Trends (2017-2022) (Million Units)
Table 26.252 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Autoimmune Disorders in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.253 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Neurological Disorders in North America, Historical Trends (2017-2022) (Million Units)
Table 26.254 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Neurological Disorders in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.255 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Other Disorders in North America, Historical Trends (2017-2022), (Million Units)
Table 26.256 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Other Disorders in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.257 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) (Million Units)
Table 26.258 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.259 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) (Million Units)
Table 26.260 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.261 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) (Million Units)
Table 26.262 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.263 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) (Million Units)
Table 26.264 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.265 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) (Million Units)
Table 26.266 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.267 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Oncological Disorders in Europe, Historical Trends (2017-2022) (Million Units)
Table 26.268 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Oncological Disorders in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.269 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Cardiovascular Disorders in Europe, Historical Trends (2017-2022) (Million Units)
Table 26.270 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Cardiovascular Disorders in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.271 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Autoimmune Disorders in Europe, Historical Trends (2017-2022) (Million Units)
Table 26.272 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Autoimmune Disorders in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.273 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Neurological Disorders in Europe, Historical Trends (2017-2022) (Million Units)
Table 26.274 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Neurological Disorders in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.275 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Other Disorders in Europe, Historical Trends (2017-2022) (Million Units)
Table 26.276 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Other Disorders in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.277 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) (Million Units)
Table 26.278 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.279 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) (Million Units)
Table 26.280 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.281 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) (Million Units)
Table 26.282 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.283 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) (Million Units)
Table 26.284 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.285 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.286 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.287 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Oncological Disorders in Asia, Historical Trends (2017-2022) (Million Units)
Table 26.288 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Oncological Disorders in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.289 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Cardiovascular Disorders in Asia, Historical Trends (2017-2022) (Million Units)
Table 26.290 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Cardiovascular Disorders in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.291 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Autoimmune Disorders in Asia, Historical Trends (2017-2022) (Million Units)
Table 26.292 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Autoimmune Disorders in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.293 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Neurological Disorders in Asia, Historical Trends (2017-2022) (Million Units)
Table 26.294 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Neurological Disorders in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.295 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Other Disorders in Asia, Historical Trends (2017-2022) (Million Units)
Table 26.296 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Other Disorders in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.297 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) (Million Units)
Table 26.298 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.299 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) (Million Units)
Table 26.300 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.301 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) (Million Units)
Table 26.302 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.303 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) (Million Units)
Table 26.304 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.305 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) (Million Units)
Table 26.306 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.307 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Oncological Disorders in Latin America, Historical Trends (2017-2022) (Million Units)
Table 26.308 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Oncological Disorders in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.309 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Cardiovascular Disorders in Latin America, Historical Trends (2017-2022) (Million Units)
Table 26.310 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Cardiovascular Disorders in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.311 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Autoimmune Disorders in Latin America, Historical Trends (2017-2022) (Million Units)
Table 26.312 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Autoimmune Disorders in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.313 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Neurological Disorders in Latin America, Historical Trends (2017-2022) (Million Units)
Table 26.314 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Neurological Disorders in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.315 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Other Disorders in Latin America, Historical Trends (2017-2022) (Million Units)
Table 26.316 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Other Disorders in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.317 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) (Million Units)
Table 26.318 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.319 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) (Million Units)
Table 26.320 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.321 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) (Million Units)
Table 26.322 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.323 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) (Million Units)
Table 26.324 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.325 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) (Million Units)
Table 26.326 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.327 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Oncological Disorders in Middle East and North Africa, Historical Trends (2017-2022) (Million Units)
Table 26.328 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Oncological Disorders in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.329 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Cardiovascular Disorders in Middle East and North Africa, Historical Trends (2017-2022) (Million Units)
Table 26.330 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Cardiovascular Disorders in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)" "
Table 26.331 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Autoimmune Disorders in Middle East and North Africa, Historical Trends (2017-2022) (Million Units)
Table 26.332 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Autoimmune Disorders in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.333 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Neurological Disorders in Middle East and North Africa, Historical Trends (2017-2022), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.334 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Neurological Disorders in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.335 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Other Disorders in Middle East and North Africa, Historical Trends (2017-2022) (Million Units)
Table 26.336 Large Volume Wearable Injectors Market for Non-Insulin Drugs targeting Other Disorders in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.337 Global Large Volume Wearable Injectors Market for Insulin, Historical Trends (2017-2022) (USD Million)
Table 26.338 Global Large Volume Wearable Injectors Market for Insulin, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.339 Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2017, 2023 and 2035 (USD Million)
Table 26.340 Large Volume Wearable Patch Pumps / Injectors Market for Insulin, Historical Trends (2017-2022), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.341 Large Volume Wearable Patch Pumps / Injectors Market for Insulin, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.342 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin, Historical Trends (2017-2022) (USD Million)
Table 26.343 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.344 Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2017, 2023 and 2035 (USD Million)
Table 26.345 Disposable Large Volume Wearable Injectors Market for Insulin Drugs, Historical Trends (2017-2022) (USD Million)
Table 26.346 Disposable Large Volume Wearable Injectors Market for Insulin, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.347 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin, Historical Trends (2017-2022) (USD Million)
Table 26.348 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.349 Large Volume Wearable Injectors Market for Insulin: Distribution by Geography, 2017, 2023 and 2035 (USD Million)
Table 26.350 Large Volume Wearable Injectors Market for Insulin in North America, Historical Trends (2017-2022) (USD Million)
Table 26.351 Large Volume Wearable Injectors Market for Insulin in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.352 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in North America, Historical Trends (2017-2022) (USD Million)
Table 26.353 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.354 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in North America, Historical Trends (2017-2022) (USD Million)
Table 26.355 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.356 Disposable Large Volume Wearable Injectors Market for Insulin in North America, Historical Trends (2017-2022) (USD Million)
Table 26.357 Disposable Large Volume Wearable Injectors Market for Insulin in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.358 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in North America, Historical Trends (2017-2022) (USD Million)
Table 26.359 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.360 Large Volume Wearable Injectors Market for Insulin in Europe, Historical Trends (2017-2022) (USD Million)
Table 26.361 Large Volume Wearable Injectors Market for Insulin in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.362 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Europe, Historical Trends (2017-2022) (USD Million)
Table 26.363 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.364 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Europe, Historical Trends (2017-2022) (USD Million)
Table 26.365 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.366 Disposable Large Volume Wearable Injectors Market for Insulin in Europe, Historical Trends (2017-2022) (USD Million)
Table 26.367 Disposable Large Volume Wearable Injectors Market for Insulin in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.368 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Europe, Historical Trends (2017-2022), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.369 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.370 Large Volume Wearable Injectors Market for Insulin in Asia, Historical Trends (2017-2022) (USD Million)
Table 26.371 Large Volume Wearable Injectors Market for Insulin in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.372 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Asia, Historical Trends (2017-2022) (USD Million)
Table 26.373 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.374 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Asia, Historical Trends (2017-2022) (USD Million)
Table 26.375 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.376 Disposable Large Volume Wearable Injectors Market for Insulin in Asia, Historical Trends (2017-2022)
Table 26.377 Disposable Large Volume Wearable Injectors Market for Insulin in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.378 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Asia, Historical Trends (2017-2022) (USD Million)
Table 26.379 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.380 Large Volume Wearable Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) (USD Million)
Table 26.381 Large Volume Wearable Injectors Market for Insulin in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.382 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) (USD Million)
Table 26.383 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.384 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) (USD Million)
Table 26.385 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.386 Disposable Large Volume Wearable Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) (USD Million)
Table 26.387 Disposable Large Volume Wearable Injectors Market for Insulin in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.388 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) (USD Million)
Table 26.389 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.390 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) (USD Million)
Table 26.391 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.392 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) (USD Million)
Table 26.393 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.394 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) (USD Million)
Table 26.395 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.396 Disposable Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) (USD Million)
Table 26.397 Disposable Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.398 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) (USD Million)
Table 26.399 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 26.400 Global Large Volume Wearable Injectors Market for Insulin, Historical Trends (2017-2022) (Million Units)
Table 26.401 Global Large Volume Wearable Injectors Market for Insulin, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.402 Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2017, 2023 and 2035 (Million Units)
Table 26.403 Large Volume Wearable Patch Pumps / Injectors Market for Insulin, Historical Trends (2017-2022) (Million Units)
Table 26.404 Large Volume Wearable Patch Pumps / Injectors Market for Insulin, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.405 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin, Historical Trends (2017-2022) (Million Units)
Table 26.406 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.407 Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2017, 2023 and 2035 (Million Units)
Table 26.408 Disposable Large Volume Wearable Injectors Market for Insulin Drugs, Historical Trends (2017-2022) (Million Units)
Table 26.409 Disposable Large Volume Wearable Injectors Market for Insulin, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.410 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin, Historical Trends (2017-2022) (Million Units)
Table 26.411 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.412 Large Volume Wearable Injectors Market for Insulin: Distribution by Geography, 2017, 2023 and 2035 (Million Units)
Table 26.413 Large Volume Wearable Injectors Market for Insulin in North America, Historical Trends (2017-2022) (Million Units)
Table 26.414 Large Volume Wearable Injectors Market for Insulin in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.415 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in North America, Historical Trends (2017-2022) (Million Units)
Table 26.416 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.417 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in North America, Historical Trends (2017-2022) (Million Units)
Table 26.418 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.419 Disposable Large Volume Wearable Injectors Market for Insulin in North America, Historical Trends (2017-2022) (Million Units)
Table 26.420 Disposable Large Volume Wearable Injectors Market for Insulin in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.421 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in North America, Historical Trends (2017-2022) (Million Units)
Table 26.422 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in North America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.423 Large Volume Wearable Injectors Market for Insulin in Europe, Historical Trends (2017-2022) (Million Units)
Table 26.424 Large Volume Wearable Injectors Market for Insulin in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.425 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Europe, Historical Trends (2017-2022) (Million Units)
Table 26.426 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.427 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Europe, Historical Trends (2017-2022) (Million Units)
Table 26.428 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.429 Disposable Large Volume Wearable Injectors Market for Insulin in Europe, Historical Trends (2017-2022) (Million Units)
Table 26.430 Disposable Large Volume Wearable Injectors Market for Insulin in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.431 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Europe, Historical Trends (2017-2022)
Table 26.432 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Europe, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.433 Large Volume Wearable Injectors Market for Insulin in Asia, Historical Trends (2017-2022) (Million Units)
Table 26.434 Large Volume Wearable Injectors Market for Insulin in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.435 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Asia, Historical Trends (2017-2022) (Million Units)
Table 26.436 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.437 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Asia, Historical Trends (2017-2022) (Million Units)
Table 26.438 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.439 Disposable Large Volume Wearable Injectors Market for Insulin in Asia, Historical Trends (2017-2022) (Million Units)
Table 26.440 Disposable Large Volume Wearable Injectors Market for Insulin in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.441 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Asia, Historical Trends (2017-2022) (Million Units)
Table 26.442 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Asia, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.443 Large Volume Wearable Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) (Million Units)
Table 26.444 Large Volume Wearable Injectors Market for Insulin in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.445 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) (Million Units)
Table 26.446 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.447 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) (Million Units)
Table 26.448 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.449 Disposable Large Volume Wearable Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) (Million Units)
Table 26.450 Disposable Large Volume Wearable Injectors Market for Insulin in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.450 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) (Million Units)
Table 26.451 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Latin America, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.452 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) (Million Units)
Table 26.453 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.454 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) (Million Units)
Table 26.455 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.456 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) (Million Units)
Table 26.457 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.458 Disposable Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) (Million Units)
Table 26.459 Disposable Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)
Table 26.460 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) (Million Units)
Table 26.460 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (Million Units)"

List of Figures

Figure 2.1 Research Methodology: Research Assumptions
Figure 2.2 Research Methodology: Project Methodology
Figure 2.3 Research Methodology: Forecast Methodology
Figure 2.4 Research Methodology: Robust Quality Control
Figure 2.5 Research Methodology: Key Market Segmentations
Figure 4.1 Executive Summary: Market Landscape of Large Volume Wearable Injectors for Non-Insulin Drugs
Figure 4.2 Executive Summary: Market Landscape of Large Volume Drug Device Combinations for Non-Insulin Drugs
Figure 4.3 Executive Summary: Market Landscape of Large Volume Wearable Injectors for Insulin Drugs
Figure 4.4 Executive Summary: Partnerships and Collaborations
Figure 4.5 Executive Summary: Patent Analysis
Figure 4.6 Executive Summary: Clinical Trial Analysis
Figure 4.7 Executive Summary: Funding and Investment Analysis
Figure 4.8 Executive Summary: Market Sizing and Opportunity Analysis for Non-Insulin Drugs
Figure 4.9 Executive Summary: Market Sizing and Opportunity Analysis for Insulin Drugs
Figure 5.1 Drug Delivery Systems
Figure 5.2 Evolution of Healthcare Safety Legislations
Figure 5.3 Large Volume Wearable Injectors Market: Key Driving Factors
Figure 5.4 Types of Self-Injection Devices
Figure 6.1 Large Volume Wearable Injectors: Distribution by Type of Device (By Drug Administered)
Figure 6.2 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Status of Development
Figure 6.3 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Device
Figure 6.4 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Usability
Figure 6.5 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Dose
Figure 6.6 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Drug Container
Figure 6.7 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Drug Filling
Figure 6.8 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Container Volume (mL)
Figure 6.9 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Route of Administration
Figure 6.10 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Injection
Figure 6.11 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Mechanism of Action / Driving Force
Figure 6.12 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Technology
Figure 6.13 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Connectivity Feature
Figure 6.14 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Compatible Drug
Figure 6.15 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Compatibility with High Viscosity Drugs
Figure 6.16 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Therapeutic Area
Figure 6.17 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution of Developers by Year of Establishment
Figure 6.18 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution of Developers by Company Size
Figure 6.19 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution of Developers by Location of Headquarters
Figure 6.20 Leading Players: Distribution by Number of Large Volume Wearable Injectors for Non-Insulin Drugs
Figure 7.1 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Status of Development
Figure 7.2 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Device
Figure 7.3 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Usability
Figure 7.4 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Dose
Figure 7.5 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Drug Container
Figure 7.6 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Mode of Drug Filling
Figure 7.7 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Container Volume (mL)
Figure 7.8 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Route of Administration
Figure 7.9 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Mode of Injection
Figure 7.10 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Compatible Drug
Figure 7.11 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Mechanism of Action / Driving Force
Figure 7.12 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Technology
Figure 7.13 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution by Therapeutic Area
Figure 7.14 Large Volume Drug Device Combinations for Non-Insulin Drugs: Distribution of Developers by Year of Establishment
Figure 7.15 Large Volume Wearable Injectors for Drug Device Combinations for Non-Insulin Drugs: Distribution of Developers by Company Size
Figure 7.16 Large Volume Wearable Injectors for Drug Device Combinations for Non-Insulin Drugs: Distribution of Developers by Location of Headquarters
Figure 7.17 Leading Players: Distribution by Number of Drug Device Combinations for Non-Insulin Drugs
Figure 8.1 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Status of Development
Figure 8.2 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Device
Figure 8.3 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Usability
Figure 8.4 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Dose
Figure 8.5 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Mode of Drug Filling
Figure 8.6 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Container Volume (mL)
Figure 8.7 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Diabetes
Figure 8.8 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Combination Insulin
Figure 8.9 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Period of use (Days)
Figure 8.10 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Device Control Feature
Figure 8.11 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Interoperable Device
Figure 8.12 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Continuous Glucose Monitoring (CGM) / Blood Glucose Meters (BGM) System
Figure 8.13 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Automatic Insulin Delivery (AID) / Artificial Pancreas
Figure 8.14 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Automated Insulin Delivery (AID) Feature
Figure 8.15 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Connectivity Feature
Figure 8.16 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Waterproof Capabilities
Figure 8.17 Large Volume Wearable Injectors for Insulin Drugs: Distribution of Developers by Year of Establishment
Figure 8.18 Large Volume Wearable Injectors for Insulin Drugs: Distribution of Developers by Company Size
Figure 8.19 Large Volume Wearable Injectors for Insulin: Distribution of Developers by Location of Headquarters
Figure 8.20 Leading Players: Analysis by Number of Large Volume Wearable Injectors for Insulin
Figure 9.1 Product Competitiveness Analysis: Large Volume Wearable Injectors Developed by Players in North America for Non-Insulin Drugs
Figure 9.2 Product Competitiveness Analysis: Large Volume Wearable Injectors Developed by Players in Europe for Non-Insulin Drugs
Figure 9.3 Product Competitiveness Analysis: Large Volume Wearable Injectors Developed by Players in Asia and MENA for Non-Insulin Drugs
Figure 9.4 Product Competitiveness Analysis: Large Volume Wearable Injectors Developed by Players in North America for Combination Products
Figure 9.5 Product Competitiveness Analysis: Large Volume Wearable Injectors Developed by Players in Europe for Combination Product
Figure 9.6 Product Competitiveness Analysis: Large Volume Wearable Injectors Developed by Players in MENA for Combination Products
Figure 9.7 Product Competitiveness Analysis: Large Volume Wearable Injectors Developed by Players in North America for Insulin Drugs
Figure 9.8 Product Competitiveness Analysis: Large Volume Wearable Injectors Developed by Players in Europe for Insulin Drugs
Figure 9.9 Product Competitiveness Analysis: Large Volume Wearable Injectors Developed by Players in Asia and MENA for Insulin Drugs
Figure 10.1 Gerresheimer: Annual Revenues, FY 2017- Q1 FY 2023 (EUR Million)
Figure 10.2 West Pharmaceuticals: Annual Revenues, FY 2017- Q1 FY 2023 (USD Billion)
Figure 10.3 Eli Lilly: Annual Revenues, FY 2017-Q1 FY 2023 (USD Billion)
Figure 10.4 Insulet: Annual Revenues, FY 2017-Q1 FY 2023 (USD Million)
Figure 10.5 Medtronic: Annual Revenues, FY 2017- FY 2023 (USD Billion)
Figure 10.6 Roche: Annual Revenues, FY 2017- Q1 FY 2023 (CHF Billion)
Figure 12.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2023
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 12.4 Partnerships and Collaborations: Distribution by Partner
Figure 12.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 12.6 Partnerships and Collaborations: Distribution by Type of Device
Figure 12.7 Most Active Players: Distribution by Number of Partnerships
Figure 12.8 Most Active Players: Distribution by Type of Partnership
Figure 12.9 Partnerships and Collaborations: Local and International Agreements
Figure 12.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 14.1 Patent Analysis: Distribution by Type of Patent
Figure 14.2 Patent Analysis: Distribution by Patent Publication Year
Figure 14.3 Patent Analysis: Distribution by Jurisdiction
Figure 14.4 Patent Analysis: Distribution by CPC Symbols
Figure 14.5 Word Cloud: Emerging Focus Areas
Figure 14.6 Patent Analysis: Cumulative Distribution by Type of Organization
Figure 14.7 Leading Industry Players: Distribution by Number of Patents
Figure 14.8 Leading Non-Industry Players: Distribution by Number of Patents
Figure 14.9 Patent Analysis: Leading Individual Assignees
Figure 14.10 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Symbols)
Figure 14.11 Patent Analysis: Distribution of Patents by Age
Figure 14.12 Large Volume Wearable Injectors: Patent Valuation
Figure 16.1 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 16.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Figure 16.3 Clinical Trial Analysis: Distribution of Enrolled Patients Population by Trial Registration Year
Figure 16.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 16.5 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 16.6 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and Trial Recruitment Status
Figure 16.7 Clinical Trial Analysis: Distribution by Study Design
Figure 16.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 16.9 Leading Players: Distribution by Number of Registered Trials
Figure 16.10 Word Cloud: Key Focus Areas
Figure 16.11Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 16.12 Most Popular Large Volume Wearable Injectors: Distribution by Number of Registered Trials
Figure 16.13 Most Popular Volume Wearable Injectors: Distribution of Trials by Phase of Development
Figure 16.14 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Figure 16.15 Clinical Trial Analysis: Distribution of Trials by Recruitment Status and Geography
Figure 17.1 Funding and Investment Analysis: Distribution of Funding Instances by Year, 2014-2023
Figure 17.2 Funding and Investment Analysis: Distribution of Amount Invested by Year, 2014-2023 (USD Million)
Figure 17.3 Funding and Investment Analysis: Distribution by Type of Funding
Figure 17.4 Funding and Investment Analysis: Distribution by Type of Device
Figure 17.5 Funding and Investment Analysis: Year-wise Distribution by Type of Funding and Amount Raised (USD Million)
Figure 17.6 Funding and Investment Analysis: Distribution by Target Disease Indication
Figure 17.7 Most Active Players: Distribution by Number of Funding Instances
Figure 17.8 Most Active Players: Distribution by Amount Invested
Figure 17.9 Leading Investors: Distribution by Number of Funding Instances
Figure 17.10 Funding and Investments: Distribution by Geography
Figure 18.1 CMOs: Distribution by Geography
Figure 19.1 Key Regulatory Authorities for Medical Devices
Figure 19.2 Medical Devices Review / Approval Process in the US
Figure 19.3 Healthcare Insurance Coverage in the US: Distribution by Type of Coverage
Figure 19.4 Medical Devices National Coverage Determination Process: US
Figure 19.5 Medical Devices Review / Approval Process in Canada
Figure 19.6 Healthcare Insurance Coverage in Canada: Distribution by Type of Coverage
Figure 19.7 Medical Devices Review / Approval Process in Mexico
Figure 19.8 Regulatory Bodies in EU5 Countries
Figure 19.9 Steps involved in CE Marking Process
Figure 19.10 Medical Devices Review / Approval Process in Europe
Figure 19.11 Medical Devices Review / Approval Process in the UK
Figure 19.12 Healthcare Insurance Coverage in the UK: Distribution by Type of Coverage
Figure 19.13 Medical Devices Reimbursement Process: UK
Figure 19.14 Healthcare Insurance Coverage in France: Distribution by Type of Coverage
Figure 19.15 Medical Devices Reimbursement Process: France
Figure 19.16 Healthcare Insurance Coverage in Germany: Distribution by Type of Coverage
Figure 19.17 Medical Devices Reimbursement Process for In-Patient Setting: Germany
Figure 19.18 Medical Devices Reimbursement Process for Out-Patient Care: Germany
Figure 19.19 Healthcare Insurance Coverage in Italy: Distribution by Type of Coverage
Figure 19.20 Medical Devices Reimbursement Process: Italy
Figure 19.21 Healthcare Insurance Coverage in Spain: Distribution by Type of Coverage
Figure 19.22 Medical Devices Reimbursement Process: Spain
Figure 19.23 Medical Devices Review / Approval Process in Australia
Figure 19.24 Healthcare Insurance Coverage in Australia: Distribution by Type of Coverage
Figure 19.25 Medical Devices Review / Approval Process in Brazil
Figure 19.26 Medical Devices Reimbursement Process: Brazil
Figure 19.27 Medical Devices Review / Approval Process in China
Figure 19.28 Healthcare Insurance Coverage in China: Distribution by Type of Coverage
Figure 19.29 Medical Devices Reimbursement Process: Shanghai
Figure 19.30 Medical Devices Review / Approval Process in India
Figure 19.31 Healthcare Insurance Coverage in Israel: Distribution by Type of Coverage
Figure 19.32 Medical Devices Review / Approval Process in Japan
Figure 19.33 Medical Devices Reimbursement Process: Japan
Figure 19.34 Healthcare Insurance Coverage in Japan: Distribution by Type of Coverage
Figure 19.35 New Medical Devices Reimbursement Process: Japan
Figure 19.36 Medical Devices Review / Approval Process in New Zealand
Figure 19.37 Healthcare Insurance Coverage in New Zealand: Distribution by Type of Coverage
Figure 19.38 Medical Devices Review / Approval Process in Singapore
Figure 19.39 Medical Devices Review / Approval Process in South Korea
Figure 19.40 Healthcare Insurance Coverage in South Korea: Distribution by Type of Coverage
Figure 19.41 Medical Devices Review / Approval Process in South Africa
Figure 19.42 Medical Devices Review / Approval Process in Taiwan
Figure 19.43 Healthcare Insurance Coverage in Taiwan: Distribution by Type of Coverage
Figure 19.44 Medical Devices Review / Approval Process in Thailand
Figure 19.45 Heat Map Analysis: Comparison of Regional Regulatory Guidelines for Medical Devices
Figure 19.46 Regulatory Control for Medical Devices: Regional Analysis by Device Risk Category
Figure 21.1 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2035
Figure 21.3 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.4 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.5 Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2035
Figure 21.6 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.7 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.8 Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2035
Figure 21.9 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.10 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.11 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.12 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.13 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.14 Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geography, 2035
Figure 21.15 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.16 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.17 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.18 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.19 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.20 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.21 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.22 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.23 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.24 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.25 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.26 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.27 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.28 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.29 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.30 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.31 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.32 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.33 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.34 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.35 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.36 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.37 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.38 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.39 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.40 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.41 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.42 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.43 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.44 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.45 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.46 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.47 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.48 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.49 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.50 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.51 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.52 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.53 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.54 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.55 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.56 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.57 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.58 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.59 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.60 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.61 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.62 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.63 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.64 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.65 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.66 Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2035
Figure 21.67 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.68 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.69 Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2035
Figure 21.70 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.71 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.72 Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2035
Figure 21.73 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.74 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.75 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.76 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.77 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.78 Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geography, 2035
Figure 21.79 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.80 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.81 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.82 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.83 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.84 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.85 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.86 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.87 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.88 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.89 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.90 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.91 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.92 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.93 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.94 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.95 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.96 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.97 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.98 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.99 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.100 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.101 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.102 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.103 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.104 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.105 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.106 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.107 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.108 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.109 Large Volume Wearable Injectors Market for Non- Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.110 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.111 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.112 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.113 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.114 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.115 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.116 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.117 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.118 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.119 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.120 Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.121 Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.122 Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.123 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.124 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.125 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.126 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.127 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 21.128 Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.1 Global Large Volume Wearable Injectors Market for Insulin, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.2 Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2035
Figure 22.3 Large Volume Wearable Patch Pumps / Injectors Market for Insulin, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.4 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.5 Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2035
Figure 22.6 Disposable Large Volume Wearable Injectors Market for Insulin, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.7 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.8 Large Volume Wearable Injectors Market for Insulin: Distribution by Geography, 2035
Figure 22.9 Large Volume Wearable Injectors Market for Insulin in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.10 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.11 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.12 Disposable Large Volume Wearable Injectors Market for Insulin in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.13 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.14 Large Volume Wearable Injectors Market for Insulin in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.15 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.16 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.17 Disposable Large Volume Wearable Injectors Market for Insulin in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.18 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.19 Large Volume Wearable Injectors Market for Insulin in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.20 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.21 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.22 Disposable Large Volume Wearable Injectors Market for Insulin in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.23 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.24 Large Volume Wearable Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.25 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.26 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.27 Disposable Large Volume Wearable Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.28 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.29 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.30 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.31 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.32 Disposable Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.33 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.34 Global Large Volume Wearable Injectors Market for Insulin, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.35 Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2035
Figure 22.36 Large Volume Wearable Patch Pumps / Injectors Market for Insulin, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.37 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.38 Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2035
Figure 22.39 Disposable Large Volume Wearable Injectors Market for Insulin, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.40 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.41 Large Volume Wearable Injectors Market for Insulin in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.42 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.43 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.44 Disposable Large Volume Wearable Injectors Market for Insulin in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.45 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.46 Large Volume Wearable Injectors Market for Insulin in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.47 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.48 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.49 Disposable Large Volume Wearable Injectors Market for Insulin in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.50 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.51 Large Volume Wearable Injectors Market for Insulin in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.52 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.53 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.54 Disposable Large Volume Wearable Injectors Market for Insulin in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.55 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.56 Large Volume Wearable Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.57 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.58 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.59 Disposable Large Volume Wearable Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.60 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.61 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.62 Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.63 Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.64 Disposable Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 22.65 Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (Million Units)
Figure 23.1 SWOT Factors: Harvey Ball Analysis
Figure 24.1 Concluding Remarks: Market Landscape of Large Volume Wearable Injectors for Non-Insulin Drugs
Figure 24.2 Concluding Remarks: Market Landscape of Large Volume Drug Device Combinations
Figure 24.3 Concluding Remarks: Market Landscape of Large Volume Wearable Injectors for Insulin Drugs
Figure 24.4 Concluding Remarks: Partnerships and Collaborations
Figure 24.5 Concluding Remarks: Key Acquisition Targets
Figure 24.6 Concluding Remarks: Patent Analysis
Figure 24.7 Concluding Remarks: Likely Drug Candidates
Figure 24.8 Concluding Remarks: Clinical Trial Analysis
Figure 24.9 Concluding Remarks: Funding and Investment Analysis
Figure 24.10 Concluding Remarks: Market Sizing and Opportunity Analysis for Large Volume Wearable Injectors for Non-Insulin Drugs
Figure 24.11 Concluding Remarks: Market Sizing and Opportunity Analysis for Large Volume Wearable Injectors for Insulin

Product Code: RA100452

INTRODUCTION

The global wearable injectors market is estimated to be worth $4.3 billion in 2023 and is expected to grow at compounded annual growth rate (CAGR) of 9.01% during the forecast period.

With the increasing population, the incidence rates of various chronic diseases, such as diabetes, autoimmune diseases, cardiovascular diseases, and oncological diseases, are witnessing an upward trend. The pharmaceutical stakeholders have made numerous efforts by incorporating innovative strategies and patient-centered approaches to address the growing burden of chronic diseases. The current treatment options include administration of prescribed medications through oral and parenteral routes. Of these options, parenteral administration of drugs is the most prevalent method. However, it lacks patient convenience due to the requirement of frequent dosing and has other limitations, including dosing errors, risk of microbial contamination, and needlestick injuries. These factors significantly impact medication adherence and consequently affect therapeutic outcomes. In recent years, the pharmaceutical industry has witnessed many technological advancements with the emergence of the novel drug delivery devices, such as wearable injectors, autoinjectors, and pen injectors. Within wearable injectors, the on-body injectors offer sustained therapeutic effects, thereby enhancing patient adherence and treatment effectiveness. In addition, large volume wearable injectors have proven to improve medication adherence by simplifying the administration process. The advanced wearable injection device provides a wide range of dosing options, such as basal, bolus, or continuous delivery. Moreover, such devices have in-built safety mechanisms, which minimize the risk of needlestick injuries. As a result, wearable injectors have become the preferred choice for subcutaneous administration of drugs in home-care settings. The popularity of wearable injectors has prompted pharmaceutical companies and medical device developers to integrate advanced features, such as artificial intelligence algorithms, mobile applications with smart health monitoring, reminders, visual and audible drug delivery confirmation notifications into their product portfolios. With continuous innovation in this field, it is expected that the adoption of such wearable injectors will increase significantly, driving market growth in the foreseen future.

SCOPE OF THE REPORT

"The Wearable Injectors Market (7^th Edition): Distribution by Type of Device (Patch Pump / On Body Injectors and Wearable Infusion Pump), Usability (Disposable and Reusable), Therapeutic Area (Autoimmune Disorders, Cardiovascular Disorders, Metabolic Disorders, Neurological Disorders, Oncological Disorders and Other Disorders) and Key Geographical Regions (North America, Europe, Asia, Latin America and Middle East and North Africa): Industry Trends and Global Forecasts, 2023-2035" report features an extensive study of the current market landscape, market size and future opportunity for the companies providing wearable injectors during the forecast period. Key inclusions of the market report are briefly discussed below.

Originally Developed for Chronic Diseases, Wearable Injectors Have Moved to Wider Markets, such as Cancer

The growing demand for wearable injectors which allow for safe self-administration of drug volumes greater than 1 mL is driven by their significant advantages. These devices offer a high level of convenience to the patients by eliminating the risk of frequent hospital visits and needle stick injuries. The wearable infusion pumps, commonly used for the administration of insulin, provide better control to the diabetic patients by preventing multiple pricks in a day. Further, on body injector, also known as patch pump, offers an effective solution to patients requiring large-volume medications or frequent dosing by simplifying the administration process and offering reminders and tracking features. The versatility of these wearable injectors makes them suitable for a wide range of medical conditions, such as diabetes, autoimmune diseases and cardiovascular disease. In addition, the wearable injectors can deliver drugs intended for other indications, such as cancer. It is worth mentioning that, in 2017, Insulet Corporation launched the first on body injector, named Onpro wearable injector. This device was employed by Amgen as a life cycle management strategy for its blockbuster drug Neulasta when its patent expired in 2015. It launched its Neulasta on-body injector, which is being sold under the name Neulasta® Onpro®. This on body injector enabled chemotherapy patients to administer a dose of pegfilgrastim post chemotherapy without requiring them to visit hospitals. The wearable injector devices cater to the specific needs of various end users. The significant benefits offered by wearable injectors, coupled with their rising demand in the pharmaceutical industry and healthcare sector, worldwide is likely to drive market growth during the forecast period.

Wearable Injectors Market Competitive Landscape

The current landscape of wearable injectors (large volume) features close to 90 devices capable of delivering insulin and non-insulin drugs. It is worth mentioning that 51% of the wearable injection devices are designed for the delivery of insulin, followed by devices (29%) and combinations (20%) used to deliver non-insulin drugs. The wearable injectors market is well-fragmented, featuring the presence of established players and start-ups that possess the required expertise to manufacture wearable injectors. Majority (over 50%) of the companies are based in North America, followed by emerging players headquartered across Europe (30%).

On Body Injector / Patch Pump are Driving the Partnership Activity

Several stakeholders have been collaborating with industry / non-industry players engaged in wearable injectors market, primarily for product / technology integration purposes. Drug developers are evaluating novel drug delivery devices for their drug candidates at preclinical stages by partnering with delivery device manufacturers. In May 2023, Viridian Therapeutics partnered with Enable Injections to evaluate its enFuse wearable injector technology for preclinical stage drug candidates. In order to cater to the growing market demand for on body injector, the device developers are also collaborating with contract manufacturing organizations to bring their devices into the market. In March 2023, Stevanato Group entered into one such collaboration with Thermo Fisher Scientific, as a part of which Stevanato provided the pre-sterilized EZ-fill cartridges and assembly equipment, while Thermo Fisher Scientific offered fill finish and final assembly services.

Owing to several advantages of on body injector, the stakeholders are also acquiring other industry players specializing in various aspects of these novel and convenient drug delivery systems. For instance, in February 2023, Insulet Corporation acquired all the patents related to a pump based insulin delivery system from Bigfoot Biomedical, in order to expand its capabilities in the wearable injectors market. In addition to this, Tandem Diabetes Care had announced the acquisition of AMF Medical in December 2022. The latter company was working on the development of an insulin patch pump / on body injector, named Sigi Patch Pump.

Wearable Infusion Pump is Mainly Used for Diabetes Care

Wearable infusion pumps are compact, lightweight devices that can be worn by patients on the belt with an attached cannula on the skin. These drug delivery devices are also known as off body injectors. These are ideal for patients who require continuous or intermittent infusions over an extended period, allowing them to move freely during the treatment. Most insulin pumps are wearable on the belt, with a tube connecting the pump to the infusion set resting in the subcutaneous fatty tissue. Various players, such as Medtronic, Tandem Diabetes Care and Roche provide wearable infusion pump for insulin delivery. According to the International Diabetes Federation, over 780 million people are expected to be living with diabetes, by 2045. Of these, a number of patients dependent on insulin are likely to move towards the use of wearable injectors, owing to their benefits associated with the improvement in quality of life. Such factors will contribute to the market growth of the wearable injectors during the forecast period.

Wearable Injectors Market Drivers: Approval of Drug-Device Combinations, Rise in Chronic Diseases and Investor Funding

Neulasta Onpro wearable injector was the first drug device combination to receive approval in 2015; since then, various drug-device combinations have received approvals. In 2016, Amgen launched the first on body injector delivering an antibody drug. The company's Pushtronex system uses West Pharmaceuticals SmartDose to deliver Repatha (evolocumab), approved for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD). The Repatha wearable injector provides an option of monthly single-dose delivery to the patients. In addition, D-mine infusion pump, offered by EVER Pharma was marketed in 2019. This drug device combination has automatic dosing function due to the micro rotation pump technology. In 2022, AbbVie launched Skyrizi on body injector which is used for the treatment of Crohn's disease. Such drug device combination approvals for non-insulin drugs are driving the wearable injectors market growth. With several pharmaceutical companies collaborating with wearable injector developers to test their devices in clinical trials, more such drug device approvals are expected during the forecast period. Furthermore, the funding received by wearable injector developers have allowed them to incorporate technological advancements into the existing designs and test their devices in clinical trials. In February 2022, Enable Injections raised USD 215 million in a Series C venture funding round. Such developments will continue to drive the wearable injectors market growth during the forecast period.

Wearable Injectors Market Size: North America will Continue to Hold the Largest Market Share

The global wearable injectors market size is estimated to be worth USD 4.3 billion in 2023. With the growing demand for effective therapeutics for the treatment of various chronic diseases, the market is anticipated to grow at a CAGR of 9.01% during the forecast period. Presently, close to 50% of the market is captured by companies based in North America. Driven by the rising interest in wearable injectors and adoption of such devices in the US, the wearable injectors market in North America is anticipated to grow at a CAGR of 10.56%, during the forecast period 2023-2035. Further, the availability of reimbursement is likely to be an important factor governing the market growth of wearable injectors, owing to the higher price points of such devices.

Leading Manufacturers in the Wearable Injectors Market

Examples of key players (which have also been profiled in this report) manufacturing wearable injectors for the delivery of insulin and non-insulin drugs include (in alphabetical order) CCBio, CeQur, Debiotech, Enable Injections, Gerresheimer, Insulet Corporation and West Pharmaceuticals. In addition to this, prominent drug device combinations include (which have also been profiled in this report) 3M™ Hollow Microstructured Transdermal System, D-mine® Pump, Repatha wearable injector and Neulasta® (pegfilgrastim) OnPro™ Kit. This market report includes an easily searchable excel database of all the wearable injector manufacturers, worldwide.

Recent Developments in Wearable Injectors Market

Several recent developments have taken place in the field of wearable injectors for the delivery of insulin and non-insulin drugs. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

In June 2023, Stevanato announced the offering of VertivaTM on-body delivery system in collaboration with Thermo Fisher Scientific.
In May 2023, Medtronic announced its plan to acquire EOFlow, manufacturer of a wearable injector EOPatch®.
Coherus Biosciences is expected to launch UDENCYA on body injector in 2023, which is currently under FDA review.

The market research report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the report includes:

A preface providing an introduction to the full report, Wearable Injectors Market, 2023-2035 (7^th Edition).
An outline of the systematic research methodology adopted to conduct the study on wearable injectors market, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of our findings.
An overview of economic factors that impact the overall large volume wearable injectors market, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
An executive summary of the insights captured during our research, offering a high-level view on the current state of wearable injectors and their likely evolution in the short to mid and long term.
A brief introduction to drug delivery devices, along with information on conventional parenteral drug delivery devices. It also highlights the key driving factors, need for improving medication adherence and different types of self-administration devices. Further, the chapter concludes with a discussion on regulatory considerations for these devices and future perspectives.
A detailed assessment of the overall market landscape of wearable injectors for the delivery of non-insulin drugs, based on several relevant parameters, including status of development (under development and commercialized), type of device (patch pumps / on body injectors and wearable infusion pumps), usability (disposable and reusable with disposable components), type of dose (basal and bolus), type of drug container (cartridges, vials, syringes and mini-bag systems), mode of drug filling (preloaded and manually loaded), container volume (mL), route of administration (subcutaneous, intravenous, intradermal and intramuscular), mode of injection (needles, cannulas and catheters), mechanism of action, type of technology, availability of connectivity feature, type of compatible drug (biologics, small molecules and others), compatibility with high viscosity drugs and therapeutic areas. In addition, the chapter presents the market landscape of companies manufacturing large volume wearable injectors for non-insulin drug delivery, including information on their year of establishment, company size (in terms of number of employees), and location of headquarters.
An overview of the current market landscape of wearable injection device and drug combinations for the delivery of non-insulin drugs, based on several relevant parameters, including status of development (under development, NDA/FDA accepted and commercialized), type of device (patch pumps / on body injectors and wearable infusion pumps), usability (disposable and reusable with disposable components), type of dose (basal and bolus), type of drug container (cartridges, drug reservoirs and vials), mode of drug filling (preloaded), container volume (mL), route of administration (subcutaneous, intravenous and others), mode of injection (needles and cannulas), type of compatible drug (biologics and small molecules), mechanism of action / driving force, type of technology and therapeutic area. Additionally, the chapter presents the market landscape of companies manufacturing drug-device combinations for non-insulin drug delivery, including information on their year of establishment, company size (in terms of number of employees), and location of headquarters.
A detailed assessment of the overall market landscape of wearable injectors for the delivery of insulin drugs, based on several relevant parameters, including status of development (under development and commercialized), type of device (patch pumps / injectors and infusion pumps / injectors), usability (disposable and reusable with disposable components), type of dose (basal and bolus), mode of drug filling (preloaded and manually loaded), container volume (mL), type of diabetes (type I and type II), type of combination insulin, period of use (days), type of device control feature (smartphone control, remote control and inbuilt control), availability of interoperable devices, availability of continuous glucose monitoring (CGM) / blood glucose meters (BGM) system, availability of automatic insulin delivery (AID) / artificial pancreas, type of automated insulin delivery feature (AID), availability of connectivity feature and waterproof capabilities. In addition, the chapter presents the market landscape of companies manufacturing large volume wearable injectors for insulin delivery, including information on their year of establishment, company size (in terms of number of employees), and location of headquarters.
A detailed product competitiveness analysis of various wearable injectors based on several relevant parameters, such as company strength (based on the experience of the company), product competitiveness (based on type of device, type of dose, container volume, usability, status of development, mode of injection, route of administration, type of drug container, type of drug compatibility, mode of drug filling, availability of connectivity feature, availability of CGM / BGM systems and waterproof capabilities) and company size (based on employee count of the product manufacturer).
Elaborate profiles of the prominent companies developing wearable injectors; each company profile features a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments, and an informed future outlook.
A list of tabulated profiles of wearable drug device combination products featuring drug specifications, mechanism of action, current status of development, dosage frequency and information on sales (if available).
An in-dept analysis of the partnerships that have been inked by the stakeholders in the wearable injectors market, during the period 2015 and 2023 based on several relevant parameters, including year of partnership, type of partnership, type of partner, type of device, most active players (in terms of number of partnerships), most active players (in terms of type of partnership) and geography.
A detailed analysis of the key acquisition targets, taking into consideration the historical trend of the acquisition activity of the players that have acquired other firms, since 2000. It offers a means for other industry stakeholders to identify potential acquisition targets.
A list of patents that have been filed / granted related to wearable injectors over the last decade. Further, it highlights analysis of patents across several relevant parameters, such as type of patent (granted patents, patent applications and others), patent publication year, jurisdiction, CPC symbol, type of organization (industry and non-industry players), emerging focus area and most active players (based on the number of patents). Additionally, the chapter includes patent benchmarking analysis and insightful patent valuation analysis, highlighting the leading patents (in terms of number of citations).
A list of marketed drugs / therapies and pipeline candidates that are likely to be developed in combination with wearable injectors in the near future, identified on the basis of an in-depth analysis of potential candidates (marketed drugs and clinical-stage drugs), taking into consideration multiple parameters, such as type of drug molecule, phase of development, indication, dosing frequency, type of therapy, method of administration and route of administration.
A detailed analysis of completed, ongoing and planned clinical trials related to wearable injectors based on several relevant parameters, such as trial recruitment status, trial registration year, trial phase, study design, type of sponsor / collaborator, leading players (based on the number of registered trials), key focus area, therapeutic area, and geography.
A detailed analysis of funding and investments made in the companies engaged in this domain, during the period 2014 and 2023, including instances of seed financing, venture capital, capital raised from IPOs, secondary offerings, grants / awards, other equity and debt financing. Further, these instances have been analyzed based on various relevant parameters, such as year of funding, amount invested by year, type of funding, type of device, target disease indication, most active players (in terms of number of funding instances and amount invested), leading investors (in terms of number of funding instances) and geography.
A case study on the role of contract manufacturing organizations in the overall manufacturing process / supply chain of wearable injectors, featuring details on the services offered by contract service providers for the manufacturing of various device components (primary containers), infusion sets, adhesives, closures, and injection moldings.
A discussion on the various guidelines established by regulatory bodies for medical device approvals across North America (US, Canada and Mexico), Europe (UK, France, Germany, Italy, Spain and rest of Europe), Asia-Pacific and rest of the world (Australia, Brazil, China, India, Israel, Japan, New Zealand, Singapore, South Africa, South Korea, Taiwan, and Thailand). The market report also features an insightful multi-dimensional heat map analysis, featuring a comparison of the contemporary regulatory and reimbursement scenarios in key geographies across the globe.
An in-depth analysis of the factors that can impact the growth of large volume wearable injectors market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.
A detailed discussion on the future opportunities of wearable injectors for large volume drug delivery. It also highlights the key parameters and trends that are likely to influence the future of this market, under a detailed SWOT framework.

One of the key objectives of the market report was to estimate the existing market size and potential future growth of wearable injectors market over the coming years. Based on parameters, such as the number of commercialized devices, number of devices under development, price of the device and the annual adoption rate, we have provided an informed estimate on the likely evolution of the wearable injectors for delivery of non-insulin drugs market over the forecast period 2023-2035. The report also features the likely distribution of the current and the forecasted opportunity across various segments, such as type of device (patch pump / injector and infusion pump / injector), usability (disposable and reusable), therapeutic area (autoimmune disorders, cardiovascular disorders, metabolic disorders neurological disorders, oncological disorders and other disorders) and key geographical regions (North America, Europe, Asia, Latin America, and Middle East and North Africa). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry's evolution.

In addition to this, report also provides a detailed market forecast analysis in order to estimate the existing market size and future opportunity for wearable injectors delivering insulin drugs over the coming years. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as type of device (patch pump / injector and infusion pump / injector), usability (disposable and reusable) and key geographical regions (North America, Europe, Asia, Latin America, and Middle East and North Africa).

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this industry.

The market report features detailed transcripts of interviews held with the following individuals:

Larry Albert (Chief Executive Officer, Qlibrium)

Michael Hooven (Chief Executive Officer, Enable Injections)

Jesper Roested (Chief Executive Officer, Subcuject)

Pieter Muntendam (former President and Chief Executive Officer, scPharmaceuticals)

Menachem Zucker (Vice President and Chief Scientist, Elcam Medical)

Graham Reynolds (former Vice President Strategic Partnerships and Business Development, West Pharmaceutical Services)

Anonymous (Ypsomed)

Eric Chappel (Engineering Project Manager / Senior System Engineer, Debiotech)

Mindy Katz (Vice President, Marketing and Alliance Management, Eitan Medical)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in this domain (academia, industry, medical practice, and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts' views

While the focus has been on forecasting the market till 2035, the market report also provides our independent views on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research, and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED:

Question 1: What is a wearable injector? What are wearable injectors?

Answer: A wearable injector is a medical device designed to deliver drugs or other medications subcutaneously in a controlled manner. It can be worn on the body like a patch or a small pump, providing a convenient and discreet method of drug administration.

Question 2: What are the advantages of wearable injectors? What are the benefits of wearable injectors?

Answer: Wearable injectors offer precise and controlled dosing of medications, ensuring accurate delivery of the required dosage. These are incorporated with safety features, such as automatic needle retraction or safety mechanisms to prevent accidental needlestick injuries. Many wearable injectors are equipped with connectivity options, allowing them to integrate with mobile apps or healthcare monitoring systems. This enables healthcare professionals to remotely monitor patient adherence, dosing patterns, and overall treatment progress, leading to better management and personalized care.

Question 3: How do you use the on-body injector Neulasta?

Answer: The on-body injector is worn directly to the skin using a self-adhesive pad. It delivers Neulasta through a subcutaneous injection.

Question 4: What is the most common type of partnership model being adopted by stakeholders engaged in this industry?

Answer: Product / technology integration agreements emerged as the most popular type of partnership model adopted by players engaged in the development of wearable injectors for the delivery of insulin and non-insulin drugs. This is followed by product development and commercialization agreements.

Question 5: Who are the key players in wearable injectors market?

Answer: Examples of key players in wearable injector market include Amgen, Becton Dickinson, CeQur, Debiotech, Enable Injection, Insulet Corporation, Tandem Diabetes Care and West Pharmaceutical Services.

Question 6: How big is the wearable injectors market?

Answer: The global wearable injectors market is projected to reach USD 12 billion by 2035.

Question 7: What is the likely growth rate (CAGR) of wearable injectors market?

Answer: The global wearable injectors market is expected to grow at a CAGR of 9.01% during the forecast period.

Question 8: Which region has the largest market share in the wearable injectors market?

Answer: Currently, North America captures close to 50% of the market share. However, it is worth highlighting that the wearable injectors market in Asia is growing at a higher pace and holds 35% of the overall share.

CHAPTER OUTLINES

Chapter 1 is a preface providing an introduction to the full report, Wearable Injectors Market, 2023-2035 (7^th Edition).

Chapter 2 is an outline of the systematic research methodology adopted to conduct the study on wearable injectors market, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of findings.

Chapter 3 provides an overview of economic factors that impact the overall wearable injectors market, which include historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.

Chapter 4 provides an executive summary of the insights captured in our research. It offers a high-level view of the current state of the wearable injectors market in the short-mid-term and long term.

Chapter 5 provides a brief introduction to drug delivery devices, along with information on conventional parenteral drug delivery devices. It also highlights the key driving factors, need for improving medication adherence and different types of self-administration devices. Further, the chapter concludes with a discussion on regulatory considerations for these devices and future perspectives.

Chapter 6 presents information on overall market landscape of wearable injectors for the delivery of non-insulin drugs, based on several relevant parameters, including status of development (under development and commercialized), type of device (patch pumps / on body injectors and wearable infusion pumps), usability (disposable and reusable with disposable components), type of dose (basal and bolus), type of drug container (cartridges, vials, syringes and mini-bag systems), mode of drug filling (preloaded and manually loaded), container volume (mL), route of administration (subcutaneous, intravenous, intradermal and intramuscular), mode of injection (needles, cannulas and catheters), mechanism of action, type of technology, availability of connectivity feature, type of compatible drug (biologics, small molecules and others), compatibility with high viscosity drugs and therapeutic areas. In addition, the chapter presents the market landscape of companies manufacturing large volume wearable injectors for non-insulin drug delivery, including information on their year of establishment, company size (in terms of number of employees), and location of headquarters.

Chapter 7 presents information of the current market landscape of wearable injection device and drug combinations for the delivery of non-insulin drugs, based on several relevant parameters, including status of development (under development, NDA/FDA accepted and commercialized), type of device (patch pumps / on body injectors and wearable infusion pumps), usability (disposable and reusable with disposable components), type of dose (basal and bolus), type of drug container (cartridges, drug reservoirs and vials), mode of drug filling (preloaded), container volume (mL), route of administration (subcutaneous, intravenous and others), mode of injection (needles and cannulas), type of compatible drug (biologics and small molecules), mechanism of action / driving force, type of technology and therapeutic area. Additionally, the chapter presents the market landscape of companies manufacturing drug-device combinations for non-insulin drug delivery, including information on their year of establishment, company size (in terms of number of employees), and location of headquarters.

Chapter 8 presents information of the overall market landscape of wearable injectors for the delivery of insulin drugs, based on several relevant parameters, including status of development (under development and commercialized), type of device (patch pumps / injectors and infusion pumps / injectors), usability (disposable and reusable with disposable components), type of dose (basal and bolus), mode of drug filling (preloaded and manually loaded), container volume (mL), type of diabetes (type I and type II), type of combination insulin, period of use (days), type of device control feature (smartphone control, remote control and inbuilt control), availability of interoperable devices, availability of continuous glucose monitoring (CGM) / blood glucose meters (BGM) system, availability of automatic insulin delivery (AID) / artificial pancreas, type of automated insulin delivery feature (AID), availability of connectivity feature and waterproof capabilities. In addition, the chapter presents the market landscape of companies manufacturing large volume wearable injectors for insulin delivery, including information on their year of establishment, company size (in terms of number of employees), and location of headquarters.

Chapter 9 presents an insightful product competitiveness analysis of wearable injectors based on several relevant parameters, such as company strength (based on the experience of the company), product competitiveness (based on type of device, type of dose, container volume, usability, status of development, mode of injection, route of administration, type of drug container, type of drug compatibility, mode of drug filling, availability of connectivity feature, availability of CGM / BGM systems and waterproof capabilities) and company size (based on employee count of the product manufacturer).

Chapter 10 provides detailed profiles of the prominent companies engaged in the development of wearable injectors. Each profile presents a brief overview of the company, financial information (if available), product portfolio, recent developments and an informed future outlook.

Chapter 11 provides tabulated profiles of wearable drug device combination products. Each profile includes drug specifications, mechanism of action, current status of development, dosage frequency and sales information (if available).

Chapter 12 features an in-depth analysis and discussion on the various partnerships inked between the players in this market, during the period 2015 and 2023, including acquisitions, product / technology integration agreements, product development and commercialization agreements, product development agreements, distribution agreements, licensing agreements, manufacturing agreements, clinical trial agreements, service agreements and other relevant agreements. The partnership instances have been further analyzed based on year of partnership, type of partnership, type of partner, type of device, most active players (in terms of number of partnerships), most active players (in terms of type of partnership) and geography.

Chapter 13 provides a detailed analysis of the key acquisition targets, taking into consideration the historical trend of the acquisition activity of the players that have acquired other firms, since 2000. It offers a means for other industry stakeholders to identify potential acquisition targets.

Chapter 14 provides an in-depth patent analysis, presenting an overview of the filed / granted patents related to large volume wearable injectors. For this analysis, we looked at the patents that have been filed by various players over the decades. The analysis has been done across type of patent (granted patents, patent applications and others), patent publication year, jurisdiction, CPC symbol, type of organization (industry and non-industry players), emerging focus area and most active players (based on the number of patents). The chapter also includes a patent benchmarking analysis and insightful patent valuation analysis, highlighting the leading patents (in terms of number of citations).

Chapter 15 presents list of marketed drugs / therapies and pipeline candidates that are likely to be developed in combination with wearable injectors in the near future, identified on the basis of an in-depth analysis of potential candidates (marketed drugs and clinical-stage drugs), taking into consideration multiple parameters, such as type of drug molecule, phase of development, indication, dosing frequency, type of therapy, method of administration and route of administration.

Chapter 16 presents a detailed analysis of completed, ongoing and planned clinical trials related to wearable injectors based on several relevant parameters, such as trial recruitment status, trial registration year, trial phase, study design, type of sponsor / collaborator, leading players (based on the number of registered trials), key focus area, therapeutic area, and geography.

Chapter 17 provides details on various investments that have been made into companies with proprietary wearable injectors, during the period 2014 and 2023, including instances of seed financing, venture capital, capital raised from IPOs, secondary offerings, grants / awards, other equity and debt financing. The investment instances have been analyzed based on various relevant parameters, such as year of funding, amount invested by year, type of funding, type of device, target disease indication, most active players (in terms of the number of funding instances), most active players (in terms of the amount invested), leading investors (in terms of the number of funding instances) and geography.

Chapter 18 includes a brief case study on the role of contract manufacturing organizations in the overall manufacturing process / supply chain of a wearable injector. It includes information on the services provided by such organizations for manufacturing of device components (primary containers), infusion sets, adhesives, closures and injection mouldings. In addition, it includes a schematic world map representation, highlighting the location of the CMOs and their device manufacturing service portfolio. Further, it also presents information on the medical devices design and development service providers.

Chapter 19 features a discussion on the various guidelines established by major regulatory bodies for medical device approvals, across North America (US, Canada and Mexico), Europe (UK, France, Germany, Italy, Spain and rest of Europe), Asia-Pacific and rest of the world (Australia, Brazil, China, India, Israel, Japan, New Zealand, Singapore, South Africa, South Korea, Taiwan, and Thailand). The report also features an insightful multi-dimensional heat map analysis, featuring a comparison of the contemporary regulatory and reimbursement scenarios in key geographies across the globe.

Chapter 20 presents an in-depth analysis of the factors that can impact the growth of large volume wearable injectors market. In addition, it includes identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.

Chapter 21 presents an insightful market forecast analysis, highlighting the future potential of wearable injectors for delivery of non-insulin drugs till the year 2035. We have segregated the opportunity across type of device (patch pump / injector and infusion pump / injector), usability (reusable and disposable), therapeutic area (autoimmune disorders, cardiovascular disorders, metabolic disorders, neurological disorders, oncological disorders and other disorders) and key geographical regions (North America, Europe, Asia, Latin America, and Middle East and North Africa).

Chapter 22 presents an insightful market forecast analysis, highlighting the future potential of wearable injectors for the delivery of insulin till the year 2035. We have segregated the opportunity across type of device (patch pump / injector and infusion pump / injector), usability (reusable and disposable) and key geographical regions (North America, Europe, Asia, Latin America, and Middle East and North Africa).

Chapter 23 presents a detailed discussion on the future opportunities of wearable injectors for large volume drug delivery. It also highlights the key parameters and trends that are likely to influence the future of this market, under a detailed SWOT framework.

Chapter 24 is a summary of the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters.

Chapter 25 is a collection of interview transcripts, featuring discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Larry Albert (Chief Executive Officer, Qlibrium), Michael Hooven (Chief Executive Officer, Enable Injections), Jesper Roested (Chief Executive Officer, Subcuject), Pieter Muntendam (former President and Chief Executive Officer, scPharmaceuticals), Menachem Zucker (Vice President and Chief Scientist, Elcam Medical), Graham Reynolds (former Vice President and General Manager, Biologics, West Pharmaceutical Services), Anonymous (Ypsomed), Eric Chappel (Engineering Project Manager / Senior System Engineer, Debiotech) and Mindy Katz (Vice President, Marketing and Alliance Management, Eitan Medical).

Chapter 26 is an appendix, which contains tabulated data and numbers for all the figures provided in the report.

Chapter 27 is an appendix, which contains a list of companies and organizations mentioned in this report.

1. PREFACE

1.1. Large Volume Wearable Injectors Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
- 2.7.1. Demographics
- 2.7.2. Economic Factors
- 2.7.3. Government Regulations
- 2.7.4. Supply Chain
- 2.7.5. COVID Impact / Related Factors
- 2.7.6. Market Access
- 2.7.7. Healthcare Policies
- 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3.1. Chapter Overview
3.2. Market Dynamics
- 3.2.1. Time Period
  - 3.2.1.1. Historical Trends
  - 3.2.1.2. Current and Forecasted Estimates
- 3.2.2. Currency Coverage
  - 3.2.2.1. Overview of Major Currencies Affecting the Market
  - 3.2.2.2. Impact of Currency Fluctuations on the Industry
- 3.2.3. Foreign Exchange Impact
  - 3.2.3.1. Evaluation of Foreign Exchange Rates and their Impact on Market
  - 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 3.2.4. Recession
  - 3.2.4.1. Historical Trends Analysis of Past Recessions and Lessons Learnt
  - 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
- 3.2.5. Inflation
  - 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

5.1. Chapter Overview
5.2. Introduction to Drug Delivery Devices
5.3. Conventional Parenteral Drug Delivery Devices
- 5.3.1. Needlestick Injuries
- 5.3.2. Incidence and Cost Burden
- 5.3.3. Prevention of Needlestick Injuries
- 5.3.4. Government Legislations for the Prevention of Needlestick Injuries
5.4. Emergence of Self-Administration Devices
- 5.4.1. Key Driving Factors
  - 5.4.1.1. Rising Burden of Chronic Diseases
  - 5.4.1.2. Healthcare Cost Savings
  - 5.4.1.3. Need for Immediate Treatment in Emergency Situations
  - 5.4.1.4. Growing Injectable Drugs Market
  - 5.4.1.5. Need for Improving Medication Adherence
5.5. Available Self-Injection Devices
- 5.5.1. Prefilled Syringes
- 5.5.2. Pen-Injectors
- 5.5.3. Needle-Free Injectors
- 5.5.4. Autoinjectors
- 5.5.5. Large Volume Wearable Injectors
5.6. Regulatory Considerations
- 5.6.1. Medical Devices
- 5.6.2. Drug Device Combination Products
5.7. Future Perspectives

6. LARGE VOLUME WEARABLE INJECTORS FOR NON-INSULIN DRUGS: CURRENT MARKET LANDSCAPE

6.1. Chapter Overview
6.2. Large Volume Wearable Injectors: Overall Market Landscape
6.3. Large Volume Wearable Injectors for Non-Insulin Drugs: Overall Market Landscape
- 6.3.1. Analysis by Status of Development
- 6.3.2. Analysis by Type of Device
- 6.3.3. Analysis by Usability
- 6.3.4. Analysis by Type of Dose
- 6.3.5. Analysis by Type of Drug Container
- 6.3.6. Analysis by Mode of Drug Filling
- 6.3.7. Analysis by Container Volume (mL)
- 6.3.8. Analysis by Route of Administration
- 6.3.9. Analysis by Mode of Injection
- 6.3.10. Analysis by Mechanism of Action / Driving Force
- 6.3.11. Analysis by Type of Technology
- 6.3.12. Analysis by Availability of Connectivity Feature
- 6.3.13. Analysis by Type of Compatible Drug
- 6.3.14. Analysis by Compatibility with High Viscosity Drugs
- 6.3.15. Analysis by Therapeutic Area
6.4. Large Volume Wearable Injectors for Non-Insulin Drugs: Developer Landscape
- 6.4.1. Analysis by Year of Establishment
- 6.4.2. Analysis by Company Size
- 6.4.3. Analysis by Location of Headquarters
- 6.3.4. Leading Players: Analysis by Number of Large Volume Wearable Injectors Manufactured for Non-Insulin Drugs

7. LARGE VOLUME DRUG DEVICE COMBINATIONS FOR NON-INSULIN DRUGS: CURRENT MARKET LANDSCAPE

7.1. Chapter Overview
7.2. Large Volume Drug Device Combinations for Non-Insulin Drugs: Overall Market Landscape
- 7.2.1. Analysis by Status of Development
- 7.2.2. Analysis by Type of Device
- 7.2.3. Analysis by Usability
- 7.2.4. Analysis by Type of Dose
- 7.2.5. Analysis by Type of Drug Container
- 7.2.6. Analysis by Mode of Drug Filling
- 7.2.7. Analysis by Container Volume (mL)
- 7.2.8. Analysis by Route of Administration
- 7.2.9. Analysis by Mode of Injection
- 7.2.10. Analysis by Type of Compatible Drug
- 7.2.11. Analysis by Mechanism of Action / Driving Force
- 7.2.12. Analysis by Type of Technology
- 7.2.13. Analysis by Therapeutic Area
7.3 Large Volume Drug Device Combinations for Non-Insulin Drugs: Developer Landscape
- 7.3.1. Analysis by Year of Establishment
- 7.3.2. Analysis by Company Size
- 7.3.3. Analysis by Location of Headquarters
- 7.3.4. Leading Players: Analysis by Number of Drug Device Combinations for Non-Insulin Drugs

8. LARGE VOLUME WEARABLE INJECTORS FOR INSULIN DRUGS: CURRENT MARKET LANDSCAPE

8.1. Chapter Overview
8.2. Large Volume Wearable Injectors for Insulin Drugs: Overall Market Landscape
- 8.2.1. Analysis by Status of Development
- 8.2.2. Analysis by Type of Device
- 8.2.3. Analysis by Usability
- 8.2.4. Analysis by Type of Dose
- 8.2.5. Analysis by Mode of Drug Filling
- 8.2.6. Analysis by Container Volume (mL)
- 8.2.7. Analysis by Type of Diabetes
- 8.2.8. Analysis by Type of Combination Insulin
- 8.2.9. Analysis by Period of Use (Days)
- 8.2.10. Analysis by Type of Device Control Feature
- 8.2.11. Analysis by Availability of Interoperable Device
- 8.2.12. Analysis by Availability of Continuous Glucose Monitoring (CGM) / Blood Glucose Meters (BGM) System
- 8.2.13. Analysis by Availability of Automatic Insulin Delivery (AID) / Artificial Pancreas
- 8.2.14. Analysis by Type of Automated Insulin Delivery (AID) Feature
- 8.2.15. Analysis by Availability of Connectivity Feature
- 8.2.16. Analysis by Waterproof Capabilities
8.3. Large Volume Wearable Injectors for Insulin Drugs: Developer Landscape
- 8.3.1. Analysis by Year of Establishment
- 8.3.2. Analysis by Company Size
- 8.3.3. Analysis by Location of Headquarters
- 8.3.4. Leading Players: Analysis by Number of Large Volume Wearable Injectors Manufactured for Insulin Drugs

9. PRODUCT COMPETITIVENESS ANALYSIS

9.1. Chapter Overview
9.2. Assumptions / Key Parameters
9.3. Methodology
9.4. Product Competitiveness Analysis: Large Volume Wearable Injectors for Non-Insulin Drugs
- 9.4.1. Products Developed by Players in North America
- 9.4.2. Products Developed by Players in Europe
- 9.4.3. Products Developed by Players in Asia and Middle East and North Africa
9.5. Product Competitiveness Analysis: Large Volume Drug Device Combinations for Non-Insulin Drugs
- 9.5.1. Products Developed by Players in North America
- 9.5.2. Products Developed by Players in Europe
- 9.5.3. Products Developed by Players in Middle East and North Africa
9.6. Product Competitiveness Analysis: Large Volume Wearable Injectors for Insulin Drugs
- 9.6.1. Products Developed by Players in North America
- 9.6.2. Products Developed by Players in Europe
- 9.6.3. Products Developed by Players in Asia and Middle East and North Africa

10. LARGE VOLUME WEARABLE INJECTOR DEVELOPERS: COMPANY PROFILES

10.1. Chapter Overview
10.2. Key Players Developing Large Volume Wearable Injectors for Non-Insulin Drugs
- 10.2.1. CCBio
  - 10.2.1.1. Company Overview
  - 10.2.1.2. Product Portfolio
  - 10.2.1.3. Recent Developments and Future Outlook
- 10.2.2. E3D Elcam Drug Delivery Devices
  - 10.2.2.1. Company Overview
  - 10.2.2.2. Product Portfolio
  - 10.2.2.3. Recent Developments and Future Outlook
- 10.2.3. Enable Injections
  - 10.2.3.1. Company Overview
  - 10.2.3.2. Product Portfolio
  - 10.2.3.3. Recent Developments and Future Outlook
- 10.2.4. Gerresheimer
  - 10.2.4.1. Company Overview
  - 10.2.4.2. Financial Information
  - 10.2.4.3. Product Portfolio
  - 10.2.4.4. Recent Developments and Future Outlook
- 10.2.5. Sonceboz
  - 10.2.5.1. Company Overview
  - 10.2.5.2. Product Portfolio
  - 10.2.5.3. Recent Developments and Future Outlook
- 10.2.6. Weibel CDS
  - 10.2.6.1. Company Overview
  - 10.2.6.2. Product Portfolio
  - 10.2.6.3. Recent Developments and Future Outlook
- 10.2.7. West Pharmaceuticals
  - 10.2.7.1. Company Overview
  - 10.2.4.2. Financial Information
  - 10.2.7.3. Product Portfolio
  - 10.2.7.4. Recent Developments and Future Outlook
10.3. Key Players Developing Large Volume Wearable Injectors for Insulin Drugs
- 10.3.1. CeQur
  - 10.3.1.1. Company Overview
  - 10.3.1.2. Product Portfolio
  - 10.3.1.3. Recent Developments and Future Outlook
- 10.3.2. Debiotech
  - 10.3.2.1. Company Overview
  - 10.3.2.2. Product Portfolio
  - 10.3.2.3. Recent Developments and Future Outlook
- 10.3.3. Eli Lilly
  - 10.3.3.1. Company Overview
  - 10.3.3.2. Financial Information
  - 10.3.3.3. Product Portfolio
  - 10.3.3.4. Recent Developments and Future Outlook
- 10.3.4. Insulet
  - 10.3.4.1. Company Overview
  - 10.3.4.2. Financial Information
  - 10.3.4.3. Product Portfolio
  - 10.3.4.4. Recent Developments and Future Outlook
- 10.3.5. Medtronic
  - 10.3.5.1. Company Overview
  - 10.3.5.2. Financial Information
  - 10.3.5.3. Product Portfolio
  - 10.3.5.4. Recent Developments and Future Outlook
- 10.3.6. Medtrum Technology
  - 10.3.6.1. Company Overview
  - 10.3.6.2. Product Portfolio
  - 10.3.6.3. Recent Developments and Future Outlook
- 10.3.7. PharmaSens
  - 10.3.7.1. Company Overview
  - 10.3.7.2. Product Portfolio
  - 10.3.7.3. Recent Developments and Future Outlook
- 10.3.8. Roche
  - 10.3.8.1. Company Overview
  - 10.3.8.2. Financial Information
  - 10.3.8.3. Product Portfolio
  - 10.3.8.4. Recent Developments and Future Outlook
- 10.3.9. SOOIL Development
  - 10.3.9.1. Company Snapshot
  - 10.3.9.2. Product Portfolio
  - 10.3.9.3. Recent Developments and Future Outlook

11. DRUG-DEVICE COMBINATIONS: DEVICE PROFILES

11.1. Chapter Overview
11.2. 3 mL Micropump (Furosemide)
11.3. 3M hMTS (Adalimumab)
11.4. D-mine Pump (Apomorphine)
11.5. FUROSCIX® On-body Infusor (Furosemide)
11.6. Herceptin sc Injection (Herceptin)
11.7. ND0612H Belt Pump (Levodopa / Carbidopa)
11.8. ND0612L Belt Pump (Levodopa / Carbidopa)
11.9. ND0612L Next Generation Patch Pump (Levodopa / Carbidopa)
11.10. ND0701 (Apomorphine)
11.11. ND0901 (Levodopa / Carbidopa)
11.12. Neulasta OnPro On-Body Injector (Neulasta or Pegfilgrastim)
11.13. Pushtronex System (Repatha or Evolocumab)
11.14. SMT-201(Ketorolac)
11.15. SMT-301 (Bupivacaine)
11.16. The LUTREPULSE System (Lutrepulse)
11.17. Trevyent (Treprostinil)
11.18. ULTOMRIS Smart Dose Injector (Ravulizumab)

12. PARTNERSHIPS AND COLLABORATIONS

12.1. Chapter Overview
12.2. Partnership Models
12.3. Large Volume Wearable Injectors: Partnerships and Collaborations
- 12.3.1. Analysis by Year of Partnership
- 12.3.2. Analysis by Type of Partnership
- 12.3.3. Analysis by Year and Type of Partnership
- 12.3.4. Analysis by Type of Partner
- 12.3.5. Analysis by Year of Partnership and Type of Partner
- 12.3.6. Analysis by Type of Device
- 12.3.7. Most Active Players: Analysis by Number of Partnerships
- 12.3.8. Most Active Players: Analysis by Type of Partnership
- 12.3.9. Analysis by Geography
  - 12.3.9.1. Local and International Agreements
  - 12.3.9.2. Intercontinental and Intracontinental Agreements

13. KEY ACQUISITION TARGETS

13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Scoring Criteria and Key Assumptions
13.4. Potential Acquisition Targets: Non-Insulin Drug Delivery Device Developers
13.5. Potential Acquisition Targets: Insulin Drug Delivery Device Developers
13.6. Concluding Remarks

14. PATENT ANALYSIS

14.1. Chapter Overview
14.2. Scope and Methodology
14.3. Large Volume Wearable Injectors: Patent Analysis
- 14.3.1. Analysis by Type of Patent
- 14.3.2. Analysis by Patent Publication Year
- 14.3.3. Analysis by Jurisdiction
- 14.3.4. Analysis by CPC Symbols
- 14.3.5. Word Cloud: Emerging Focus Areas
- 14.3.6. Analysis by Type of Organization
- 14.3.7 Most Active Players: Analysis by Number of Patents
14.4. Large Volume Wearable Injectors: Patent Benchmarking Analysis
- 14.4.1. Analysis by Patent Characteristics
14.5. Large Volume Wearable Injectors: Patent Valuation Analysis

15. LARGE VOLUME WEARABLE INJECTORS: LIKELY DRUG CANDIDATES

15.1. Chapter Overview
15.2. Marketed Drugs
- 15.2.1. Most Likely Candidates for Delivery via Large Volume Wearable Injectors
- 15.2.2. Likely Candidates for Delivery via Large Volume Wearable Injectors
- 15.2.3. Less Likely Candidates for Delivery via Large Volume Wearable Injectors
- 15.2.4. Least Likely Candidates for Delivery via Large Volume Wearable Injectors
15.3. Clinical stage Drugs

16. CLINICAL TRIAL ANALYSIS

16.1. Chapter Overview
16.2. Scope and Methodology
16.3. Large Volume Wearable Injectors: Clinical Trial Analysis
- 16.3.1. Analysis by Trial RecruitmentStatus
- 16.3.2. Analysis by Trial Registration Year
- 16.3.3 Analysis of Enrolled Patent Population by Trial Registration Year
- 16.3.4. Analysis by Trial Phase
- 16.3.5. Analysis of Enrolled Patient Population by Trial Phase
- 16.3.6. Analysis by Trial Registration Year and Trial Recruitment Status
- 16.3.7. Analysis by Study Design
- 16.3.8. Analysis by Type of Sponsor / Collaborator
- 16.3.9. Leading Players: Analysis by Number of Registered Trials
- 16.3.10. Word Cloud: Key Focus Areas
- 16.3.11. Analysis by Therapeutic Area
- 16.3.12. Most Popular Large Volume Wearable Injectors: Analysis by Number of Registered Trials
- 16.3.13. Analysis by Geography
- 16.3.14. Analysis by Trial Recruitment Status and Geography
- 16.3.15. Analysis of Enrolled Patient Population by Trial Recruitment Status and Geography

17. FUNDING AND INVESTMENT ANALYSIS

17.1. Chapter Overview
17.2. Types of Funding
17.3. Large Volume Wearable Injectors: Funding and Investment Analysis
- 17.3.1. Analysis by Year of Funding
- 17.3.2. Analysis of Amount Invested by Year
- 17.3.3. Analysis by Type of Funding
- 17.3.4. Analysis by Type of Device
- 17.3.5. Analysis of Amount Invested by Year and Type of Funding
- 17.3.6. Analysis of Amount Invested by Type of Device
- 17.3.7. Analysis by Target Disease Indication
- 17.3.8. Most Active Players: Analysis by Number of Funding Instances
- 17.3.9. Most Active Players: Analysis by Amount Invested
- 17.3.10. Leading Investors: Analysis by Number of Funding Instances
- 17.3.11. Analysis by Geography

18. CASE STUDY: ROLE OF CONTRACT MANUFACTURING ORGANIZATIONS IN DEVICE DEVELOPMENT SUPPLY CHAIN

18.1. Chapter Overview
18.2. Device Development Supply Chain
18.3. Role of Contract Manufacturing Organizations (CMOs) in Device Development
18.4. List of CMOs
- 18.4.1. Geographical Distribution of CMOs
18.5 Medical Devices Design and Development Service Providers

19. REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES

19.1. Chapter Overview
19.2. General Regulatory and Reimbursement Guidelines for Medical Devices
19.3. Regulatory and Reimbursement Landscape in North America
- 19.3.1. The US Scenario
  - 19.3.1.1. Regulatory Authority
  - 19.3.1.2. Review / Approval Process
  - 19.3.1.3. Reimbursement Landscape
    - 19.3.1.3.1. Payer Mix
    - 19.3.1.3.2. Reimbursement Process
- 19.3.2. The Canadian Scenario
  - 19.3.2.1. Regulatory Authority
  - 19.3.2.2. Review / Approval Process
  - 19.3.2.3. Reimbursement Landscape
    - 19.3.2.3.1. Payer Mix
    - 19.3.2.3.2. Reimbursement Process
- 19.3.3. The Mexican Scenario
  - 19.3.3.1. Regulatory Authority
  - 19.3.3.2. Review / Approval Process
  - 19.3.3.3. Reimbursement Landscape
    - 19.3.3.3.1. Payer Mix
19.4. Regulatory and Reimbursement Landscape in Europe
- 19.4.1. Overall Scenario
  - 19.4.1.1. Overall Regulatory Authority
  - 19.4.1.2. Overall Review / Approval Process
- 19.4.2. The UK Scenario
  - 19.4.2.1. Regulatory Authority
  - 19.4.2.2. Review / Approval Process
  - 19.4.2.3. Reimbursement Landscape
    - 19.4.2.3.1. Payer Mix
    - 19.4.2.3.2. Reimbursement Process
- 19.4.3. The French Scenario
  - 19.4.3.1. Regulatory Authority
  - 19.4.3.2. Review / Approval Process
  - 19.4.3.3. Reimbursement Landscape
    - 19.4.3.3.1. Payer Mix
    - 19.4.3.3.2. Reimbursement Process
- 19.4.4. The German Scenario
  - 19.4.4.1. Regulatory Authority
  - 19.4.4.2. Review / Approval Process
  - 19.4.4.3. Reimbursement Landscape
    - 19.4.4.3.1. Payer Mix
    - 19.4.4.3.2. Reimbursement Process
- 19.4.5. The Italian Scenario
  - 19.4.5.1. Regulatory Authority
  - 19.4.5.2. Review / Approval Process
  - 19.4.5.3. Reimbursement Landscape
    - 19.4.5.3.1. Payer Mix
    - 19.4.5.3.2. Reimbursement Process
- 19.4.6. The Spanish Scenario
  - 19.4.6.1. Regulatory Authority
  - 19.4.6.2. Review / Approval Process
  - 19.4.6.3. Reimbursement Landscape
    - 19.4.6.3.1. Payer Mix
    - 19.4.6.3.2. Reimbursement Process
19.5. Regulatory and Reimbursement Landscape in Asia-Pacific and Rest of the World
- 19.5.1. The Australian Scenario
  - 19.5.1.1. Regulatory Authority
  - 19.5.1.2. Review / Approval Process
  - 19.5.1.3. Reimbursement Landscape
    - 19.5.1.3.1. Payer Mix
    - 19.5.1.3.2. Reimbursement Process
- 19.5.2. The Brazilian Scenario
  - 19.5.2.1. Regulatory Authority
  - 19.5.2.2. Review / Approval Process
  - 19.5.2.3. Reimbursement Landscape
    - 19.5.2.3.1. Payer Mix
    - 19.5.2.3.2. Reimbursement Process
- 19.5.3. The Chinese Scenario
  - 19.5.3.1. Regulatory Authority
  - 19.5.3.2. Review / Approval Process
  - 19.5.3.3. Reimbursement Landscape
    - 19.5.3.3.1. Payer Mix
    - 19.5.3.3.2. Reimbursement Process
- 19.5.4. The Indian Scenario
  - 19.5.4.1. Regulatory Authority
  - 19.5.4.2. Review / Approval Process
  - 19.5.4.3. Reimbursement Landscape
    - 19.5.4.3.1. Payer Mix
- 19.5.5. The Israeli Scenario
  - 19.5.5.1. Regulatory Authority
  - 19.5.5.2. Review / Approval Process
  - 19.5.5.3. Reimbursement Landscape
    - 19.5.5.3.1. Payer Mix
- 19.5.6. The Japanese Scenario
  - 19.5.6.1. Regulatory Authority
  - 19.5.6.2. Review / Approval Process
  - 19.5.6.3. Reimbursement Landscape
    - 19.5.6.3.1. Payer Mix
    - 19.5.6.3.2. Reimbursement Process
- 19.5.7. The New Zealand Scenario
  - 19.5.7.1. Regulatory Authority
  - 19.5.7.2. Review / Approval Process
  - 19.5.7.3. Reimbursement Landscape
    - 19.5.7.3.1. Payer Mix
    - 19.5.7.3.2. Reimbursement Process
- 19.5.8. The Singaporean Scenario
  - 19.5.8.1. Regulatory Authority
  - 19.5.8.2. Review / Approval Process
  - 19.5.8.3. Reimbursement Landscape
    - 19.5.8.3.1. Payer Mix
    - 19.5.8.3.2. Reimbursement Process
- 19.5.9. The South Korean Scenario
  - 19.5.9.1. Regulatory Authority
  - 19.5.9.2. Review / Approval Process
  - 19.5.9.3. Reimbursement Landscape
    - 19.5.9.3.1. Payer Mix
    - 19.5.9.3.2. Reimbursement Process
- 19.5.10. The South African Scenario
  - 19.5.10.1. Regulatory Authority
  - 19.5.10.2. Review / Approval Process
  - 19.5.10.3. Reimbursement Landscape
- 19.5.11. The Taiwanese Scenario
  - 19.5.11.1. Regulatory Authority
  - 19.5.11.2. Review / Approval Process
  - 19.5.11.3. Reimbursement Landscape
    - 19.5.11.3.1. Payer Mix
    - 19.5.11.3.2. Reimbursement Process
- 19.5.12. The Thailand Scenario
  - 19.5.12.1. Regulatory Authority
  - 19.5.12.2. Review / Approval Process
  - 19.5.12.3. Reimbursement Landscape
19.6. Comparison of Regional Regulatory Environment
19.7. Concluding Remarks

20. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

20.1. Chapter Overview
20.2. Market Drivers
20.3. Market Restraints
20.4. Market Opportunities
20.5. Market Challenges
20.6. Conclusion

21. MARKET SIZING AND OPPORTUNITY ANALYSIS FOR LARGE VOLUME WEARABLE INJECTORS FOR NON-INSULIN DRUGS

21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Estimates (2023-2035) (By Value)
- 21.3.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2035 (By Value)
  - 21.3.1.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
  - 21.3.1.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
- 21.3.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2035 (By Value)
  - 21.3.2.1. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
  - 21.3.2.2. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
- 21.3.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2035 (By Value)
  - 21.3.3.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
  - 21.3.3.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
  - 21.3.3.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
  - 21.3.3.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
  - 21.3.3.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
- 21.3.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geography, 2035 (By Value)
  - 21.3.4.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.1.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.1.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.1.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.1.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.1.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.1.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.1.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.1.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.1.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
  - 21.3.4.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.2.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.2.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.2.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.2.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.2.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.2.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.2.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.2.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.2.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
  - 21.3.4.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.3.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.3.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.3.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.3.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.3.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.3.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.3.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.3.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.3.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
  - 21.3.4.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.4.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.4.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.4.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.4.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.4.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.4.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.4.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.4.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.4.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
  - 21.3.4.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.4.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.4.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.4.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.4.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.4.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.4.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.4.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.4.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 21.3.4.4.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.4. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
- 21.4.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2035 (By Volume)
  - 21.4.1.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
  - 21.4.1.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
- 21.4.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2035 (By Volume)
  - 21.4.2.1. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
  - 21.4.2.2. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
- 21.4.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2035 (By Volume)
  - 21.4.3.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
  - 21.4.3.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
  - 21.4.3.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
  - 21.4.3.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
  - 21.4.3.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
- 21.4.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geography, 2035 (By Volume)
  - 21.4.4.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.1.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.1.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.1.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.1.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.1.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.1.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.1.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.1.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.1.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
  - 21.4.4.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.2.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.2.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.2.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.2.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.2.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.2.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.2.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.2.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.2.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
  - 21.4.4.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.3.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.3.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.3.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.3.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.3.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.3.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.3.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.3.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.3.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
  - 21.4.4.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.4.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.4.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.4.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.4.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.4.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.4.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.4.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.4.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.4.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
  - 21.4.4.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.4.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.4.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.4.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.4.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.4.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.4.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.4.4.4.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.3.4.4.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 21.3.4.4.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
21.5 Concluding Remarks

22. MARKET SIZING AND OPPORTUNITY ANALYSIS FOR LARGE VOLUME WEARABLE INJECTORS FOR INSULIN

22.1. Chapter Overview
22.2. Forecast Methodology and Key Assumptions
22.3. Global Large Volume Wearable Injectors Market for Insulin, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
- 22.3.1. Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2035 (By Value)
  - 22.3.1.1. Large Volume Wearable Patch Pumps / Injectors Market for Insulin, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
  - 22.3.1.2. Large Volume Wearable Infusion Pumps / Injectors Market for Insulin, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
- 22.3.2. Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2035 (By Value)
  - 22.3.2.1. Disposable Large Volume Wearable Injectors Market for Insulin, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
  - 22.3.2.2. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
- 22.3.3. Large Volume Wearable Injectors Market for Insulin: Distribution by Geography, 2035 (By Value)
  - 22.3.3.1. Large Volume Wearable Injectors Market for Insulin in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 22.3.3.1.1. Large Volume Wearable Patch Pumps / Injectors Market for Insulin in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 22.3.3.1.2. Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 22.3.3.1.3. Disposable Large Volume Wearable Injectors Market for Insulin in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 22.3.3.1.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
  - 22.3.3.2. Large Volume Wearable Injectors Market for Insulin in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 22.3.3.2.1. Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 22.3.3.2.2. Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 22.3.3.2.3. Disposable Large Volume Wearable Injectors Market for Insulin in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 22.3.3.2.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
  - 22.3.3.3. Large Volume Wearable Injectors Market for Insulin in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 22.3.3.3.1. Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 22.3.3.3.2. Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 22.3.3.3.3. Disposable Large Volume Wearable Injectors Market for Insulin in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 22.3.3.3.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
  - 22.3.3.4. Large Volume Wearable Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 22.3.3.4.1. Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 22.3.3.4.2. Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 22.3.3.4.3. Disposable Large Volume Wearable Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 22.3.3.4.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
  - 22.3.3.5. Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 22.3.3.5.1. Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 22.3.3.5.2. Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 22.3.3.5.3. Disposable Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
    - 22.3.3.5.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
22.4. Global Large Volume Wearable Injectors Market for Insulin, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
- 22.4.1. Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2035 (By Volume)
  - 22.4.1.1. Large Volume Wearable Patch Pumps / Injectors Market for Insulin, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
  - 22.4.1.2. Large Volume Wearable Infusion Pumps / Injectors Market for Insulin, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
- 22.4.2. Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2035 (By Volume)
  - 22.4.2.1. Disposable Large Volume Wearable Injectors Market for Insulin, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
  - 22.4.2.2. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
- 22.4.3. Large Volume Wearable Injectors Market for Insulin: Distribution by Geography, 2035 (By Value)
  - 22.4.3.1. Large Volume Wearable Injectors Market for Insulin in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 22.4.3.1.1. Large Volume Wearable Patch Pumps / Injectors Market for Insulin in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 22.4.3.1.2. Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 22.4.3.1.3. Disposable Large Volume Wearable Injectors Market for Insulin in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 22.4.3.1.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
  - 22.4.3.2. Large Volume Wearable Injectors Market for Insulin in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 22.4.3.2.1. Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 22.4.3.2.2. Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 22.4.3.2.3. Disposable Large Volume Wearable Injectors Market for Insulin in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 22.4.3.2.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
  - 22.4.3.3. Large Volume Wearable Injectors Market for Insulin in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 22.4.3.3.1. Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 22.4.3.3.2. Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 22.4.3.3.3. Disposable Large Volume Wearable Injectors Market for Insulin in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 22.4.3.3.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
  - 22.4.3.4. Large Volume Wearable Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 22.4.3.4.1. Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 22.4.3.4.2. Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 22.4.3.4.3. Disposable Large Volume Wearable Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 22.4.3.4.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
  - 22.4.3.4. Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 22.4.3.4.1. Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 22.4.3.4.2. Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 22.4.3.4.3. Disposable Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
    - 22.4.3.4.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
22.5 Concluding Remarks

23. SWOT ANALYSIS

23.1. Chapter Overview
23.2. SWOT Analysis
- 23.2.1. Strengths
- 23.2.2. Weaknesses
- 23.2.3. Opportunities
- 23.2.4. Threats
23.3. Large Volume Wearable Injectors: Future Growth Opportunities
- 23.3.1. Rising Focus on Self-Administration of Drugs
- 23.3.2. Possibility of Integration with Mobile Applications
- 23.3.3. Potential Life Cycle Management Tool
- 23.3.4. Potential Usability for Multiple Therapeutic Areas

24. CONCLUDING REMARKS

25. EXECUTIVE INSIGHTS

25.1. Chapter Overview
25.2. Qlibrium
- 25.2.1. Company Snapshot
- 21.2.2. Interview Transcript: Larry Albert, Chief Executive Officer
25.3. Enable Injections
- 25.3.1. Company Snapshot
- 25.3.2. Interview Transcript: Michael Hooven, Chief Executive Officer
25.4. Subcuject
- 25.4.1. Company Snapshot
- 25.4.2. Interview Transcript: Jesper Roested, Chief Executive Officer
25.5. scPharmaceuticals
- 25.5.1. Company Snapshot
- 25.5.2. Interview Transcript: Pieter Muntendam, former President and Chief Executive Officer
25.6. Elcam Medical
- 25.6.1. Company Snapshot
- 25.6.2. Interview Transcript: Menachem Zucker, Vice President and Chief Scientist
25.7. West Pharmaceutical Services
- 25.7.1. Company Snapshot
- 25.7.2. Interview Transcript: Graham Reynolds, Former Vice President and General Manager, Biologics
25.8. Ypsomed
- 25.8.1. Company Snapshot
- 25.8.2. Interview Transcript: Anonymous
25.9. Debiotech
- 25.9.1. Company Snapshot
- 25.9.2. Interview Transcript: Eric Chappel, Engineering Project Manager / Senior System Engineer
25.10. Eitan Medical
- 25.10.1. Company Snapshot
- 25.10.2. Interview Transcript: Mindy Katz, Vice President, Marketing and Alliance Management

ウェアラブルインジェクターの世界市場（第7版）：デバイスタイプ別（パッチポンプ／オンボディインジェクター／ウェアラブル輸液ポンプ）、使用性別、治療領域別、主要地域別：業界動向と予測（2023年～2035年）

Wearable Injectors Market (7th Edition): Distribution by Type of Device (Patch Pump / On Body Injector and Wearable Infusion Pump), Usability, Therapeutic Area and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

目次

第1章 序文

第2章 調査手法

第3章 経済およびその他のプロジェクト特有の考慮事項

第4章 エグゼクティブサマリー

第5章 イントロダクション

第6章 非インスリン薬用の大容量ウェアラブルインジェクター：現在の市場情勢

第7章 非インスリン薬用の大容量薬剤-医療機器コンビネーション製品：現在の市場情勢

第8章 インスリン薬用の大容量ウェアラブルインジェクター：現在の市場情勢

第9章 製品の競争力分析

第10章 大容量ウェアラブルインジェクター開発者：企業プロファイル

第11章 コンビネーション薬剤：デバイスプロファイル

第12章 パートナーシップとコラボレーション

第13章 主要な取得目標

第14章 特許分析

第15章 大容量ウェアラブルインジェクター：有望な薬剤候補

第16章 臨床試験の分析

第17章 資金調達と投資の分析

第18章 ケーススタディ：デバイス開発サプライチェーンにおける受託製造組織の役割

第19章 医療機器の規制と償還の情勢

第20章 市場への影響分析：促進要因、抑制要因、機会、課題

第21章 非インスリン薬用の大容量ウェアラブルインジェクターの市場規模と機会分析

第22章 インスリン薬用の大容量ウェアラブルインジェクターの市場規模と機会分析

第23章 SWOT分析

第24章 結論

第25章 経営陣の洞察

第26章 付録1：表形式のデータ

第27章 付録2：企業および組織のリスト

List of Tables

List of Figures

INTRODUCTION

SCOPE OF THE REPORT

Originally Developed for Chronic Diseases, Wearable Injectors Have Moved to Wider Markets, such as Cancer

Wearable Injectors Market Competitive Landscape

On Body Injector / Patch Pump are Driving the Partnership Activity

Wearable Infusion Pump is Mainly Used for Diabetes Care

Wearable Injectors Market Drivers: Approval of Drug-Device Combinations, Rise in Chronic Diseases and Investor Funding

Wearable Injectors Market Size: North America will Continue to Hold the Largest Market Share

Leading Manufacturers in the Wearable Injectors Market

Recent Developments in Wearable Injectors Market

The market report features detailed transcripts of interviews held with the following individuals:

RESEARCH METHODOLOGY

The secondary sources of information include:

KEY QUESTIONS ANSWERED:

Question 1: What is a wearable injector? What are wearable injectors?

Question 2: What are the advantages of wearable injectors? What are the benefits of wearable injectors?

Question 3: How do you use the on-body injector Neulasta?

Question 4: What is the most common type of partnership model being adopted by stakeholders engaged in this industry?

Question 5: Who are the key players in wearable injectors market?

Question 6: How big is the wearable injectors market?

Question 7: What is the likely growth rate (CAGR) of wearable injectors market?

Question 8: Which region has the largest market share in the wearable injectors market?

CHAPTER OUTLINES

TABLE OF CONTENTS

1. PREFACE

2. RESEARCH METHODOLOGY

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

4. EXECUTIVE SUMMARY

5. INTRODUCTION

6. LARGE VOLUME WEARABLE INJECTORS FOR NON-INSULIN DRUGS: CURRENT MARKET LANDSCAPE

7. LARGE VOLUME DRUG DEVICE COMBINATIONS FOR NON-INSULIN DRUGS: CURRENT MARKET LANDSCAPE

8. LARGE VOLUME WEARABLE INJECTORS FOR INSULIN DRUGS: CURRENT MARKET LANDSCAPE

9. PRODUCT COMPETITIVENESS ANALYSIS

10. LARGE VOLUME WEARABLE INJECTOR DEVELOPERS: COMPANY PROFILES

11. DRUG-DEVICE COMBINATIONS: DEVICE PROFILES

12. PARTNERSHIPS AND COLLABORATIONS

13. KEY ACQUISITION TARGETS

14. PATENT ANALYSIS

15. LARGE VOLUME WEARABLE INJECTORS: LIKELY DRUG CANDIDATES

16. CLINICAL TRIAL ANALYSIS

17. FUNDING AND INVESTMENT ANALYSIS

18. CASE STUDY: ROLE OF CONTRACT MANUFACTURING ORGANIZATIONS IN DEVICE DEVELOPMENT SUPPLY CHAIN

19. REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES

20. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

21. MARKET SIZING AND OPPORTUNITY ANALYSIS FOR LARGE VOLUME WEARABLE INJECTORS FOR NON-INSULIN DRUGS

22. MARKET SIZING AND OPPORTUNITY ANALYSIS FOR LARGE VOLUME WEARABLE INJECTORS FOR INSULIN

23. SWOT ANALYSIS

24. CONCLUDING REMARKS

第1章序文

第2章調査手法

第3章経済およびその他のプロジェクト特有の考慮事項

第4章エグゼクティブサマリー

第5章イントロダクション

第6章非インスリン薬用の大容量ウェアラブルインジェクター：現在の市場情勢

第7章非インスリン薬用の大容量薬剤-医療機器コンビネーション製品：現在の市場情勢

第8章インスリン薬用の大容量ウェアラブルインジェクター：現在の市場情勢

第9章製品の競争力分析

第10章大容量ウェアラブルインジェクター開発者：企業プロファイル

第11章コンビネーション薬剤：デバイスプロファイル

第12章パートナーシップとコラボレーション

第13章主要な取得目標

第14章特許分析

第15章大容量ウェアラブルインジェクター：有望な薬剤候補

第16章臨床試験の分析

第17章資金調達と投資の分析

第18章ケーススタディ：デバイス開発サプライチェーンにおける受託製造組織の役割

第19章医療機器の規制と償還の情勢

第20章市場への影響分析：促進要因、抑制要因、機会、課題

第21章非インスリン薬用の大容量ウェアラブルインジェクターの市場規模と機会分析

第22章インスリン薬用の大容量ウェアラブルインジェクターの市場規模と機会分析

第24章結論

第25章経営陣の洞察

第26章付録1：表形式のデータ

第27章付録2：企業および組織のリスト